Wayne State University
Wayne State University Dissertations

1-1-2013

Fatty Acid Fate In Determining Oxidation And
Inflammation In Adipose Tissue
Emilio Patrick Mottillo
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Endocrinology Commons, and the Medicine and Health Sciences Commons
Recommended Citation
Mottillo, Emilio Patrick, "Fatty Acid Fate In Determining Oxidation And Inflammation In Adipose Tissue" (2013). Wayne State
University Dissertations. Paper 678.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

FATTY ACID FATE IN DETERMINING OXIDATION AND INFLAMMATION IN
ADIPOSE TISSUE
by

EMILIO PATRICK MOTTILLO
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2013
MAJOR: PATHOLOGY
Approved By:

Advisor

Date

DEDICATION
“Nel mezzo del cammin di nostra vita
mi ritrovai per una selva oscura
che' la diritta via era smarrita.”

– Dante Alighieri La Divina Commedia – Inferno
“...ma gia volgena il mio disio e'l velle
si come rota ch'igualmente e mossa,
l'Amor che muove il sole e l'altre stelle”

– Dante Alighieri La Divina Commedia – Paradiso
To my wife, Sabrina, I thank you for your love and support down this long and arduous road.
Your love truly does move the sun and the stars.

“e quindi uscimmo a riveder le stelle"

– Dante Alighieri La Divina Commedia – Inferno
To my children, Liliana and Cristiano, I thank you for bringing a smile to my face each and every
day. You truly are the stars in my life.

ii

ACKNOWLEDGEMENTS
First and foremost, I would like to thank my advisor, Dr. James Granneman for sharing
his wealth of knowledge.

Dr. Granneman’s mentorship has sculpted my growth as an

independent researcher. He has taught me that one needs to a well rounded multi-disciplinary
scientist, and I only hope that I can be as knowledgeable as him.
I would like to thank my committee members for their support throughout this work. I
thank Drs. Leff and Mackenzie for their insightful scientific conversations. I believe that my
success is a reflection of the training that I received in the CIMER group. I thank Drs. Fridman
and Sheng for pushing me to think beyond the details and consider the big picture.
In addition, to past and current lab members, I thank them for their help and support
along the way. To my colleague, Dr. Yun-Hee Lee, I thank you for your expertise and for
advancing work in our laboratory. I am grateful to Dr. Meng-Jer Lee for providing mass-spec
data on sphingolipids, and for his collaborative effort. I thank Dr. Diglio, my initial graduate
advisor, for his help in the transition to becoming a graduate student. To Dr. Vickie Kimler, I
thank you for your editing expertise.

iii

PREFACE
This thesis is based upon the following published papers:
1. Mottillo E.P., X.J. Shen, J.G. Granneman. β3-adrenergic receptor induction of adipocyte
inflammation requires lipolytic activation of p38 and JNK. BBA - Molecular and Cell
Biology of Lipids. Sep;1801(9):1048-55
2. Mottillo E.P. and J.G. Granneman (2011). Intracellular fatty acids suppress β-adrenergic
induction of PKA-targeted gene expression in white adipocytes. Am J Physiol Endocrinol
Metab., 301(1), E122-31.
3. Mottillo E.P., Block A.E., Leff T. and J.G. Granneman (2012). Lipolytic products activate
peroxisome proliferator-activated receptor (PPAR) α and δ in brown adipocytes to
match fatty acid oxidation with supply. J. Biol. Chem. 287: 25038-48.
4. Lee Y.H*, Mottillo E.P.* and J.G. Granneman (2013). Adipose Tissue Plasticity from WAT
to BAT and in between. BBA Molecular Basis of Disease. Invited review, in submission.
*Equal contribution

iv

TABLE OF CONTENTS
Dedication...................................................................................................................................... ii
Acknowledgements....................................................................................................................... iii
Preface.......................................................................................................................................... iv
List of Figures.............................................................................................................................. viii
Chapter 1. Introduction................................................................................................................ 1
1.1 Adipose tissue and obesity.......................................................................................... 1
1.2 Function of adipose tissue........................................................................................... 2
1.3 White and brown adipose tissue................................................................................. 3
1.4 Lipolysis and fatty acid fate in adipocytes.................................................................... 4
1.5 Obesity and inflammation............................................................................................ 6
1.6 Therapeutic remodelling of adipose tissue by targeting β3-Adrenergic Receptors.... 8
1.7 Peroxisome proliferator-activated receptors (PPARs)............................................... 10
1.8 Lipolysis and PPAR signaling...................................................................................... 12
1.9 Hypothesis and aim of the project............................................................................. 13
Chapter 2. Materials and Methods............................................................................................ 15
2.1 Animal studies............................................................................................................ 15
2.2 Cell culture and in vitro assays................................................................................... 16
2.3 Liquid chromatography–mass spectrometry (LC-MS)/MS quantification of
ceramides and sphingolipids............................................................................................ 17
2.4 cAMP measurements................................................................................................. 18
2.5 siRNA knockdowns..................................................................................................... 19
2.6 Lentivirus Transduction.............................................................................................. 19
v

2.7 Reporter assays.......................................................................................................... 20
2.8 Generation of reporter constructs............................................................................. 21
2.9 Live cell imaging......................................................................................................... 21
2.10 Quantification of cellular FFAs................................................................................. 22
2.11 Quantification of FFAs and glycerol by biochemical methods................................. 23
2.12 RNA extraction and gene expression analysis.......................................................... 23
2.13 Protein isolation and western blot analysis............................................................. 24
2.14 Quantification of mitochondrial DNA content......................................................... 25
2.15 Measurement of mitochondrial respiration............................................................ 25
2.16 Statistical analysis.................................................................................................... 26
Chapter 3. Intracellular fatty acids promote the expression of inflammatory cytokines in
white adipocytes.................................................................................................................... 27
3.1 Expression of inflammatory cytokines by β-AR activation is mediated by intracellular
fatty acids......................................................................................................................... 27
3.2 The induction of PAI-1 is partly mediated by ceramides/sphingolipids..................... 29
3.3 Chapter 3 Discussion.................................................................................................. 31
Chapter 4. Intracellular fatty acids limit the induction of oxidative genes in WAT................. 33
4.1 Inhibition of HSL potentiates β3-AR gene expression in WAT................................... 33
4.2 Limiting lipolysis potentiates β-AR induction of PKA-targeted genes in 3T3-L1
adipocytes........................................................................................................................ 36
4.3 Intracellular fatty acids reduce β-AR-coupled gene expression in 3T3-L1
adipocytes........................................................................................................................ 39
4.4 Fatty acids blunt β-AR induction of cAMP by inhibiting adenylyl cyclase.................. 41
vi

4.5 Limiting lipolysis increases mitochondrial activity and promotes CL-induced fat
loss................................................................................................................................... 44
4.6 Chapter 4 Discussion.................................................................................................. 46
Chapter 5. Lipolytic products activate PPARα and δ in brown adipocytes to match fatty acid
oxidation with supply................................................................................................................. 49
5.1 Lipolysis is required for the maximal induction of thermogenic gene expression by
β-AR in brown adipocytes and BAT................................................................................. 49
5.2 Increasing fatty acids promotes thermogenic gene transcription in brown
adipocytes........................................................................................................................ 55
5.3 PPARα and PPARδ mediate the induction of thermogenic genes by β-AR
activation......................................................................................................................... 57
5.4 Lipid droplets generate ligands that can transcriptionally activate PPAR α and δ,
But not PPARγ.................................................................................................................. 60
5.5 Knockdown of ATGL reduces PKA upregulation of mitochondrial gene expression
and fatty acid oxidation................................................................................................... 65
5.6 Chapter 5 Discussion.................................................................................................. 70
Chapter 6. General Discussion................................................................................................... 72
Chapter 7. Future Directions...................................................................................................... 78
7.1 To further determine the signals that promote inflammation in WAT during β3-AR
activation......................................................................................................................... 78
7.2 To further determine the trafficking of fatty acids within cells................................. 78
7.3 To determine whether direct activation of lipolysis is of benefit in rodents............. 79
7.4 To determine whether ATGL is required for the browning of white fat.................... 79
References................................................................................................................................... 80
Abstract...................................................................................................................................... 100
Autobiographical Statement...................................................................................................... 102

vii

LIST OF FIGURES
Figure 1: Fatty acid fates in adipocytes....................................................................................... 28
Figure 2: Intracellular FFAs promote the induction of CCL2 and PAI-1 by β-AR activation........ 30
Figure 3: The induction of PAI-1 is partly mediated by de novo ceramides/sphingolipids......... 35
Figure 4: Reducing lipolysis by inhibition or genetic deletion of HSL potentiates PKA-targeted
genes during β3-AR activation in white adipose tissue of mice.................................. 36
Figure 5: Inhibition of HSL in 3T3-L1 adipocytes potentiates β-AR induction of PKA-targeted
genes............................................................................................................................ 38
Figure 6: Knockdown of ATGL potentiates β-AR induction of PKA-targeted genes.................... 38
Figure 7: Intracellular fatty acids suppress the expression of β-AR targeted genes................... 40
Figure 8: Fatty acids suppress cAMP/PKA signalling at the level of adenylyl cyclase................. 43
Figure 9: Partial inhibition of lipolysis enhances markers of white fat browning and
mitochondrial activity, and promotes fat loss in mice................................................ 45
Figure 10: Limiting lipolysis promotes β3-AR signalling in WAT................................................. 47
Figure 11: HSL is required for β3-AR mediated induction of thermogenic genes in BAT........... 50
Figure 12: HSL is required for β-AR mediated induction of oxidative genes in brown
adipocytes.................................................................................................................. 52
Figure 13: Knockdown of ATGL reduces the induction of oxidative genes by β-AR activation
in brown adipocytes.................................................................................................. 54
Figure 14: Endogenous fatty acids increase the transcription of genes involved in
thermogenesis in brown adipocytes.......................................................................... 56
Figure 15: Antagonists against PPARα and δ, but not PPARγ reduce the induction of
thermogenic genes by β-AR activation in brown adipocytes................................... 58
Figure 16: Knockdown of PPARα and δ reduces the induction of thermogenic genes by
β-AR activation in brown adipocytes......................................................................... 60
Figure 17: Ligands for PPARα and δ, but not PPARγ are created at the lipid droplet surface in
response to lipolysis.................................................................................................. 62
viii

Figure 18: PPAR fluorescent reporters are correctly targeting to lipid droplets........................ 63
Figure 19: Fatty acids are sufficient to activate PPARα and δ..................................................... 64
Figure 20: Lipolysis stimulates PPARα and δ transcriptional activity.......................................... 65
Figure 21: ATGL is required to maximally increase mitochondrial gene expression in
response to cAMP stimulation in brown adipocytes................................................. 67
Figure 22: ATGL is required to maximally increase fatty acid oxidation in response to cAMP
stimulation in brown adipocytes............................................................................... 69
Figure 23: Lipolytic products activate PPARα and δ to promote lipid oxidation in BAT............. 71
Figure 24: Lipolytic products in white fat balance production with efflux.................................. 72
Figure 25: Lipolytic products in BAT match supply with oxidation........................................... 75

ix

1

Chapter 1. Introduction
1.1

Adipose tissue and obesity
The incidence of obesity has been increasing over the past 20 years in the United States,

with current rates greater than 27%, and is slowly becoming a global problem (Caballero 2007).
Obesity is a major risk factor for cardiovascular disease, dyslipidemia, certain types of cancer,
and is strongly correlated with type 2 diabetes mellitus (MMWR 2006). Although excessive
adiposity is the most prominent feature of obesity, recent research indicates that disease risk is
most related ability of adipose tissue (AT) to act as an energy buffer and not total fat mass
(Adilson Guilherme et al. 2008). For instance, Cowden syndrome, which is due to mutations in
phosphatase and tensin homolog, causes obesity, yet patients are insulin sensitive (Pal et al.
2012). Conversely, patients with familial partial lipodystrophy develop a loss of subcutaneous
fat, along with severe insulin resistance and diabetes (Hegele et al. 2007). Similarly in rodents,
genetic models that limit adipose tissue expansion during overnutrition promote ectopic lipid
accumulation and exacerbate diabetes (Wang et al. 2008). On the other hand, increasing the
storage capacity of WAT reduces ectopic triglyceride (TG) accumulation and improves insulin
sensitivity (Kim et al. 2007).
Central to excess adiposity causing diabetes are free fatty acids (FFAs). Excess FAs are toxic
to cells, therefore the ability of white adipose tissue (WAT) to store and control their release is
essential. During obesity, excess FFAs lead to inflammation in WAT and whole body insulin
resistance. Conversely, treatment with the anti-diabetic thiazolidinedione (TZD) drugs, limits
FFA release by promoting fat storage, and improves insulin action, despite promoting greater
weight gain (Seufert et al. 2004). The excess weight gain is not ideal in terms of the stigma
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associated with obesity and the consequent poor quality of life. An alternative strategy to limit
the effects of toxic FA is to promote their combustion within adipose tissue, providing the same
beneficial effects, but without increased adiposity. This can be done by activating adipocyte β3adrenergic receptors (AR) which stimulate thermogenesis in brown adipose tissue (BAT),
increase whole body energy expenditure, and have anti-obesity and anti-diabetic effects in
rodents (Ghorbani, Claus, and Himms-Hagen 1997, Grujic et al. 1997).
The mechanisms by which β3-ARs improve whole body metabolism are not completely
understood, however, a central component is the mobilization of FFAs. In BAT, mobilized FFAs
activate uncoupling protein 1 (UCP1), the molecular effector of thermogenesis, and provide fuel
for sustained heat production. Thus, FFAs are necessary and sufficient to drive thermogenesis.
Although acute mobilization of FFAs would be expected to promote inflammation in WAT,
chronic activation of β3-AR appears to expand the ability of fat to oxidize fatty acids in situ,
thereby lowering systemic FFAs and improving insulin action, while at the same time reducing
adiposity. Thus, focusing on FA fate within WAT and BAT will be critical in understanding how
activation of the β3-AR produces reciprocal responses of inflammation and oxidation.

1.2

Function of adipose tissue
Adipose tissue has long been considered an inert storage depot for excess energy;

however, AT is now known to be a dynamic regulator of whole body insulin sensitivity and
metabolism (Attie and Scherer 2009).

AT normally functions as a buffer during energy

imbalance, storing nutrients as TG in times of excess, and mobilizing FFAs in times of need.
Because FFAs and their metabolic products can be toxic, homeostatic mechanisms exist to
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finely balance lipid storage and mobilization so that potentially toxic lipids do not accumulate in
peripheral organs (Unger 2002). The ability of adipose tissues to buffer variations in energy
supply and demand is achieved by mechanisms which allow fat cells to sequester excess energy
and mobilize it in times of deficit. In addition, AT can regulate whole body metabolism by
releasing hormones, termed adipokines, that control energy intake as well as promote energy
utilization in peripheral tissues (Prins 2002). As such, the function of the adipose organ (Cinti
2001) is to prevent detrimental accumulation of surplus energy in non-adipose tissues.
However, during chronic overnutrition the buffering capacity and hormonal control of adipose
tissue is impaired, resulting in the spillover of lipids from fat tissue and the pathological
accumulation of lipids within key insulin sensitive tissues. The formation of ectopic lipid
suppresses insulin sensitivity in muscle and liver, and insulin production by the pancreas in a
process termed lipotoxicity (Unger 2002, Unger and Scherer 2010). Thus, one might anticipate
that promoting lipid storage in adipose tissue or increasing FA oxidation might have beneficial
effects on whole body metabolism.

1.3

White and brown adipose tissue
Historically, AT tissue has been divided into WAT and BAT based upon anatomical

location, morphology and function. WAT is the main site for storage of TG and contains
unilocular fat cells that have sparse mitochondria. WAT can be subdivided into subcutaneous
depots found beneath the skin, and visceral (also called abdominal fat) depots found
surrounding the internal organs. Visceral fat drains directly into the hepatoportal systems and is
associated with poor metabolic profile and displays characteristics of inflammation in obese
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rodents and humans. On the other hand, subcutaneous fat is thought to have a protective
function in metabolic disorders (Gesta, Tseng, and Kahn 2007). In contrast to WAT, BAT is a
thermogenic organ with dense sympathetic innervation and a well developed vasculature that
functions to maintain body temperature in response to cold exposure (Cannon and Nedergaard
2004). BAT is located in the anterior and dorsal regions which reflects its function as the main
heater organ in rodents and larger mammals (Symonds et al. 2011). Morphologically, BAT
contains multilocular fat cells with abundant mitochondria containing UCP1. In contrast to
WAT, FFAs mobilized in BAT activate UCP1 (Fedorenko, Lishko, and Kirichok 2012), and supply
fuel for high rates of oxidative metabolism. Thus, lipolysis serves different functions in WAT vs.
BAT.

1.4

Lipolysis and fatty acid fate in adipocytes
TGs are stored and released from organelles termed lipid droplets. Lipid droplets are

the site of lipolysis, which is a highly dynamic and regulated process. Adipocyte lipolysis is
mediated by the stimulation of the β-AR which triggers adenylyl cyclase (AC) to elevate cAMP
levels and activate protein kinase A (PKA). PKA phosphorylates the lipid droplet protein
perilipin 1 (Plin1), which releases the co-lipase abhydrolase domain containing 5 (Abhd5) and
thereby activates adipose triglyceride lipase (ATGL) (Granneman and Moore 2008). PKA also
phosphorylates hormone sensitive lipase (HSL) a major diacyglycerol (DAG) lipase (Kraemer and
Shen 2002). In this fashion, ATGL releases the initial FA from the sn-2 position of TG to produce
DAG, allowing HSL to release a FA and monoacylglycerol, in which monoglyceride lipase
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releases the last FA and glycerol (Eichmann et al. 2012). In addition to being an energy source,
FFAs can also mediate other biological effects.
FFAs liberated from TG within adipocytes can have multiple fates (Figure 1). During
lipolysis, FFAs are primarily released from white adipocytes into systemic circulation where they
can be utilized as an energy source by tissues such as skeletal muscle and heart. In order to
undergo intracellular metabolism, FAs need to be first activated in an ATP dependent manner.
This is done by acyl-CoA synthetase, forming a fatty-acyl-CoA, thus trapping FFAs within cells
(Thompson, Lobo, and Bernlohr 2010).

Once activated, FFAs are catabolized in the

mitochondria via β-oxidation, or targeted toward glycerolipid or phospholipid formation.
Furthermore, FFAs are also thought to be ligands for the peroxisome proliferator activated
receptors (PPARs), which are transcription factors that regulate various aspects of lipid
metabolism (Evans, Barish, and Wang 2004). In addition, FFAs generated by lipolysis impact
cellular signaling by negatively regulating cAMP generation in cells (Fain and Shepherd 1979).
Finally, FFAs are known to cause inflammation in WAT during β3-AR activation (Granneman et
al. 2005) and are strongly implicated in the etiology of adipose inflammation during obesity
(Adilson Guilherme et al. 2008).
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Figure 1. Fatty acid fates in adipocytes. Stimulation of β3-AR promotes PKA activity, leading
to direct activation of gene transcription within the nucleus (N) and activation of lipolysis
(ATGL and HSL). Fatty acids liberated by lipases have various fates within a fat cell: 1), FFAs
can act in a negative feedback manner on adenylyl cyclase (AC); 2), can promote
inflammation; 3), burned up as energy by via β-oxidation in mitochondria; or 4), act as
signaling molecules for nuclear receptors.

1.5

Obesity and inflammation
The identification of obese adipose tissue as a source of pro-inflammatory cytokines

prompted a plethora of research into how inflammation in AT precipitates diabetes (Weisberg
et al. 2003). Numerous studies demonstrate that obesity in mice elevates the expression of
inflammatory cytokines such as chemokine (C-C motif) ligand 2 (CCL2), plasminogen activator
inhibitor-1 (PAI-1) and interleukin 6 (IL-6), and recruits of activated macrophages (Cinti et al.
2005, Lumeng, Bodzin, and Saltiel 2007, Weisberg et al. 2006, Weisberg et al. 2003).
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Importantly, genetic and/or pharmacological interventions that reduce AT inflammation,
improve systemic insulin sensitivity (Goldfine, Fonseca, and Shoelson 2011, Weisberg et al.
2006). While numerous mechanisms have been proposed as to how obesity causes
inflammation in adipose tissue, the more accepted mechanisms include formation of
hypertrophic fat cells and production of lipid mediators.
Chronic overnutrition increases the occurrence of hypertrophic fat cells, which upon
reaching a critical size become distressed and undergo a necrotic/apoptotic cell death (Cinti et
al. 2005). Distressed fat cells send out signals, such as CCL2, which recruits macrophages that
form a syncytium surrounding fat cells, termed a crown like structures (CLS) (Lumeng, Bodzin,
and Saltiel 2007, Weisberg et al. 2006). These macrophages are thought to be of the proinflammatory type and are an important source of inflammatory cytokines (Lumeng, Bodzin,
and Saltiel 2007).

The formation of CLS further triggers an inflammatory response in

surrounding cells and impedes the buffering of FAs in fat cells of mice (A. Guilherme et al. 2008)
and in cultured human cells (Wentworth et al. 2010). However, the contribution of fat cells to
cytokine expression is not well understood. This systemic low-grade inflammation disrupts the
balance between FA storage and mobilization in adipose tissue, which promotes ectopic lipid
accumulation and subsequent production of lipid mediators in non-adipose tissue.

For

example, saturated FAs can activate the innate immune signaling pathway Toll-like receptor 4
(TLR4) to mount an inflammatory response, which can then suppress insulin action (Nguyen et
al. 2007).

However, the direct role of TLR4 in promoting insulin resistance remains

controversial (Murumalla et al. 2012, Orr et al. 2012). In addition, metabolites of FAs such as
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DAGs and ceramides can also promote inflammation and impair insulin signaling (Glass and
Olefsky 2012, Holland et al. 2011).
A drawback of high fat diet studies is that they involve long term treatment over
months to mediate their effects, and there is a strong dissociation between early change in fat
cell function and the final outcome of adipose tissue inflammation and insulin resistance.
However, the β3-AR provides a tractable model to understand how FFAs produce inflammation
in WAT which occurs over hours. Thus, understanding the mechanisms of how activation of β3AR produces inflammation and means of increasing lipid oxidation that limit toxic fatty acids
could be useful in treating obesity and improving insulin action.

1.6

Therapeutic remodelling of adipose tissue by targeting β3-Adrenergic Receptors
As mentioned in the beginning of the chapter (1.1), one means of addressing the

adverse metabolic consequences of obesity is to promote the combustion of FFAs within AT by
activating β3-ARs. β3-AR agonists improve metabolism in rodent models of type 2 diabetes by
expanding the ability of brown and white adipose tissues to oxidize FAs in situ, and thereby
prevent systemic lipotoxicity. Although β3-AR agonists have not been successful in humans
(Arch 2011, Arch 2008), this does not preclude their study in rodents. Their experimental use in
rodents can uncover parallel mechanisms that can be targeted pharmacologically, which could
have use in humans. Moreover, the recent identification that adult humans have significant
BAT depots raises the possibility of utilizing BAT therapeutically (Ravussin and Kozak 2009,
Ravussin and Galgani 2011).

9
In rodents, physiological or pharmacological stimulation of β3-ARs activates brown fat
by mobilizing FFAs, thus sharply elevating FA oxidation and metabolic rate (Arch et al. 1984,
Yoshida et al. 1994). The anti-diabetes effects of β3-AR agonists require chronic treatment
(Yoshida et al. 1994), and are correlated with dramatic remodeling of WAT (Granneman et al.
2005, Li et al. 2005). Initially, activation of the β3-AR produces a transient inflammatory state
in WAT, marked by the expression of inflammatory cytokines and recruitment of myeloid cells
(Granneman et al. 2005). However, with chronic stimulation the inflammation wanes as WAT is
transformed from a lipid storage organ, into one that can oxidize FAs. This “browning” of WAT
is marked by the appearance of numerous multilocular brown adipocytes (BAs), and the
upregulation of genes involved in FA oxidation and mitochondrial biogenesis (Granneman et al.
2005). Understanding the mechanisms of β3-AR is of importance since activation of BAT, and
browning of WAT (Vegiopoulos et al. 2010) can have anti-obesity effects and improve glucose
homeostasis and insulin sensitivity in rodents (Ghorbani, Claus, and Himms-Hagen 1997, Grujic
et al. 1997). Moreover, the recent identification that human BAs are more similar to BA
recruited in rodent WAT (Sharp et al. 2012, Wu et al. 2012), suggests that browning of WAT
may be of therapeutic benefit.
The mechanisms by which β3-ARs enhance the catabolic character of brown fat and the
browning of WAT are not completely understood, but likely involve synergy among various
signalling pathways (Collins, Yehuda-Shnaidman, and Wang 2010, Kozak 2011). Many of the
factors involved in enhancing BAT thermogenesis, or promoting the browning of WAT, likely lie
downstream of the cAMP/PKA signalling node (Cao et al. 2004, Kozak 2011, Rim and Kozak
2002). One such critical factor is peroxisome proliferator-activated receptor gamma coactivator
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1α (PGC1α), which is a transcriptional co-activator of nuclear receptors (Puigserver et al. 1998).
PGC1α was initially described as a cold-induced mRNA transcript, and is necessary for the
maximal induction of UCP1 mRNA, and is a master regulator of mitochondrial biogenesis (Chang
et al. 2012, Puigserver et al. 1998, M. Uldry et al. 2006). Importantly, PGC1α in adipose tissue is
critical for cold-adaptive thermogenesis (Chang et al. 2012, Kleiner et al. 2012). In addition,
PGC1α and peroxisome proliferator-activated receptor α (PPARα), a nuclear receptor that is
involved in lipid signaling, have been identified as genes associated with maximal induction of
UCP1 expression in WAT depots (Xue et al. 2005).
Stimulation of the β3-AR/PKA pathway promotes the transcription of thermogenic
genes such as PGC1α and UCP1 genes.

Exactly how β-ARs promote thermogenic gene

transcription is not entirely known, but PKA phosphorylates CREB (Reusch, Colton, and Klemm
2000, Rim and Kozak 2002), thereby activating transcription via cAMP response elements (CRE)
(Karamitri et al. 2009). In addition, the genes for UCP1 and PGC1α contain binding sites for the
PPAR nuclear receptors.

1.7

Peroxisome proliferator-activated receptors (PPARs)
The nuclear receptors PPARα, PPARδ and PPARγ are activated by various lipid species

and regulate FA oxidation and lipid storage (Lee, Olson, and Evans 2003). PPARγ is highly
expressed in adipose tissue (Chawla, Schwarz et al. 1994) and is a master regulator of adipocyte
differentiation (Tontonoz, Hu et al. 1994; Hu, Tontonoz et al. 1995; Lehmann, Moore et al.
1995) (reviewed in Spiegelman 1998). Thus, expression and activation of PPARγ is necessary
and sufficient to induce adipogenesis in cultured embryonic fibroblasts (Rosen, Sarraf et al.
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1999). While the endogenous ligand(s) of PPARγ are not certain (Kliewer, Sundseth et al. 1997),
it is clear that TZDs are potent and selective agonists of this receptor (Lehmann, Moore et al.
1995; Berger, Bailey et al. 1996) (reviewed in Spiegelman 1998). In humans, TZDs ameliorate
insulin resistance and increase peripheral glucose utilization and uptake in various target tissues
and improve serum lipid levels (Seufert, Lubben et al. 2004). On the other hand, PPARα is
highly expressed is oxidative tissues such as heart, liver and BAT. Consistent with this pattern
of expression, PPARα has a critical role in controlling FA oxidation and is the target for the lipidlowering agents fibrates (Evans, Barish, and Wang 2004). Much less is known about PPARδ
which is ubiquitously expressed in humans and rodents (Ahmed et al. 2007, Evans, Barish, and
Wang 2004); however there is a growing appreciation that PPARδ also regulates FA oxidation.
Overexpression of PPARδ upregulates the expression of genes involved in thermogenesis and
protects mice from diet-induced obesity (Wang et al. 2003). Thus it seems that PPARs have
opposing function on lipid metabolism with PPARγ promoting the storage of lipids, while PPARα
and δ promoting lipid oxidation. Interestingly, long-chain FAs are potent activators of PPARα
and δ in vitro, but have weak to no activity on PPARγ (Forman, Chen, and Evans 1997). While
the therapeutic benefits of targeting the PPARs are widely known (Ahmed et al. 2007), how
these receptors are activated in a biological context and the cellular site(s) of ligand production
are less well understood. However, growing evidence suggests that lipolytic products are
important source of PPAR ligands.
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1.8

Lipolysis and PPAR signaling
The earliest indication that activating lipolysis could alter PPAR activity was from studies

of the β3-AR agonists. Activation of the β3-AR stimulates lipolysis and also promotes the
expression of PPAR target genes (Granneman et al. 2005), however, whether the pathways of
lipolysis and gene transcription interact, is not known. Subsequent genetic manipulations that
increase lipolysis such as loss or overexpression of Plin1 (Castro-Chavez et al. 2003, Sawada et
al. 2010) or overexpression of ATGL (Ahmadian et al. 2009), enhances the catabolic phenotype
of WAT with increased mitochondrial mass and upregulation of genes involved in FA oxidation.
In contrast, Mice lacking ATGL in AT have reduced expression of PPARα target genes in BAT
(Ahmadian et al. 2011). Furthermore, the upregulation of genes involved in lipid catabolism by
β3-AR activation is delayed in WAT of mice lacking HSL (Mottillo, Shen, and Granneman 2007).
In other tissues ATGL is needed to maintain an oxidative phenotype in the heart (Haemmerle et
al. 2011), and Abhd5 regulates skeletal muscle lipolysis and oxidative metabolism in a PPARδdependent manner (Badin et al. 2012). Overall, these studies suggest that increasing lipolysis
may be beneficial, provided that oxidative tissues, including adipose tissue, are able to counter
excess FFA flux by increasing FA oxidation and/or handling. However, a direct demonstration
that lipolysis can alter PPAR activity is lacking. Furthermore, the above studies did not address
whether lipases can produce direct ligands that modify the transcriptional activity of PPARs.
FAs are toxic and the inability to counter excess FFAs can produce inflammation. This
relationship is best exemplified in PPARα KO mice that have been challenged with the β3-AR
agonist. Normally activation of the β3-AR produces a transient inflammatory response in WAT
that wanes as FA oxidation is increased in situ. PPARα KO mice display a constant and
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heightened inflammatory state in white fat in response to continuous β3-AR agonist treatment
and are unable to upregulate a FA oxidation program (Li et al. 2005). The upregulation of lipid
oxidation in WAT is chronic adaption that balances flux with oxidation, however, counter
responses might exist to acutely limit FFAs and prevent excessive mobilization. One such
mechanism could be the ability of FFAs to inhibit the production of cAMP. On the other hand,
FFAs drive thermogenesis in BAT in which lipolysis is balanced with oxidation. However, very
little work has been done to understand how FA fate differs between WAT and BAT. Thus, by
focusing on the fate of FAs, the work proposed below will provide an integrative
comprehension of how the β3-AR produces contrasting phenomena in WAT and BAT.

1.9

Hypothesis and aim of the project
The organizing hypothesis of this work is that the differential response produced by β3-

AR activation in WAT and BAT is dependent on the fate of FFAs.

Our previous work that

activation of the β3-AR produces inflammation in WAT, and current findings lead to the
following specific hypothesis: 1) intracellular FAs mobilized by lipolysis promote the expression
of inflammatory cytokines in white adipocytes. 2) Intracellular FAs are feedback inhibitors of
the cAMP/PKA pathway to limit the expression of PKA target genes. 3) Lipolysis in brown
adipocytes (BAs) and BAT activates the nuclear receptors PPARs to promote lipid oxidation.
The goal of this dissertation is to understand the signalling mechanisms of lipolysis, and
to identify how FFAs mediate the differential responses in WAT and BAT. This hypothesis will
be tested by three specific aims: 1) to understand the mechanisms by which FAs promote the
expression of inflammatory cytokines. 2) To determine the role of lipolysis in the expression of
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oxidative genes in WAT and the browning of WAT. 3) To determine the role of lipolysis in
promoting an oxidative phenotype in BAT.
Overall, the above aims are part of a main objective to understand how metabolic
pathways interact with transcriptional events in adipose tissue, and the functional significance
of these interactions. In a broader sense, these objectives will help determine if activating
lipolysis might be of therapeutic benefit, and if targeting lipolysis pharmacologically is a feasible
approach in a clinical setting. Data generated from these experiments will improve our
understanding of adipocyte biology, providing valuable information on the differential roles of
lipolysis in mediating inflammation and oxidation. Finally, data obtained from these studies
may contribute to the development of new anti-obesity therapies that which promote an
oxidative phenotype in WAT and activation of BAT in humans.
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Chapter 2. Materials and Methods
2.1

Animal studies
All animal protocols were approved by Institutional Animal Care and Use Committee

(IACUC) and the Division of Laboratory Animal Resources (DLAR) at Wayne State University.
HSL-KO mice were supplied by Dr. F. Kraemer (Stanford University). HSL+/− mice on a C57Bl/6
(BL6) background were bred at Wayne State University. Mice were genotyped by PCR using
primers HSL-A, 5′AGAGAGACCAACTCAGCCTCCCAC-3′; HSL-B, 5′CAAGGTGTCTGTCTGTGCTGTCTT3′; and SI-166, 5′AGGATTGGGAAGACAATAGCAGGCAT-3′; where PCR of the WT allele generates
a 269-base pair (bp) band and the mutant allele a 320-bp band. Male or female mice were
injected intraperitoneally (IP) with the β3-AR agonist (CL 316,243; CL, 10 nmol), and 6 h later,
epididymal white adipose tissue (EWAT) and BAT were collected and stored in RNALater
(Ambion) at -80 °C.
To examine the effects of pharmacological inhibition of HSL, 8 week old male BL6 mice
(n=7-8) were pretreated with 30 mg/kg of the selective HSL inhibitor BAY 59-9435, 4-isopropyl3-methyl-2-[1-(3-(S)-methyl-piperidin-1-yl)-methanoyl]-2H-isoxalo-5-one (BAY) (Claus et al.
2005), suspended in 0.5% methylcellulose or methylcellulose alone via oral gavage. After one
hour, mice were injected IP with 10 nmol of CL or H2O, and sacrificed 3 hr later and EWAT or
BAT was removed and stored as above. For measurement of plasma FAs and glycerol, blood
was collected via retro-orbital bleed 45 min after CL treatment. Studies to examine the subacute effects of HSL inhibition were performed on male BL6 mice and treated daily for five days
with BAY (30mg/kg) or MC via gavage, followed by an injection of CL (10 nmol) or saline 1 h
later. Body composition was determined by NMR (EchoMRI) prior to drug treatment (day 0)
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and after 5 days. In situ electron transport chain activity was examined in EWAT minces by
measuring the reduction of 2,3,5-triphenyltetrazolium chloride (TTC, Sigma), as previously
described (Li et al. 2005).

2.2

Cell culture and in vitro assays
The 3T3-L1 cell line was used as a cell culture model for adipocytes.

The cells were

originally derived from Swiss mouse embryos by Dr. Howard Green (Green and Kehinde 1975).
Cells as fibroblasts were obtained from ATCC (CL-173) and maintained in DMEM with 10%
bovine calf serum (BCS). Fibroblasts were differentiated as previously described (Moore et al.
2005). Briefly, cells were grown to confluency in BCS. Two day post-confluency (Day 0), media
was changed to Differentiation I media (DMEM 10% fetal bovine serum [FBS], 1 ug/ml insulin,
0.5 mM IBMX [3-isobutyl-1-methylxanthine], 1 uM dexamethasome) and maintained for three
days. Media was then changed to Differentiation media II (DMEM 10% FBS 1 ug/ml insulin).
Two days after, cells were maintained in DMEM 10% FBS, and experiments were performed on
adipocytes with greater than 90% differentiation on days 13-14.

One day prior to the

experiment, adipocytes were cultured overnight in DMEM (Invitrogen), and media was replaced
with serum-free, phenol red-free, DMEM (Mediatech) containing 0.1 % FA free bovine serum
albumin (BSA) (Roche Diagnostics) unless indicated otherwise. Differentiated adipocytes were
pretreated for 1 h with the selective HSL inhibitor BAY (5 μM), inhibitor of serine
palmitoyltransferase (SPT) (Myriocin, 10 µM), or vehicle (DMSO) then stimulated with 10 μM
isoproterenol or H2O (control) for 3 h. In other experiments cells were treated with the HSL
inhibitor BAY (5 µM) or DMSO for 30 min followed by forskolin (FSK) (4 µM; Sigma) or the cAMP
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analogue 8-Br-cAMP (1 mM; Sigma) for 3 h. Long-chain acyl-CoA synthetase (ACSL) activity was
inhibited with triacsin C (5 µM; Sigma) for 30 min followed by isoproterenol treatment (10 µM,
3 h).
A BA cell line derived from mouse fetal brown fat and subsequently transformed with
SV40 large T antigen, was cultured and differentiated as previously described (Marc Uldry et al.
2006). Briefly, confluent cells were placed in induction media (0.5 mM IBMX); 0.25 mM
indomethacin; 2 µg/ml dexamethasone; 1 nM T3, 20 nM insulin) for two days and subsequently
maintained on differentiation media (1 nM T3, 20 nM insulin).

All experiments were

performed on cultures 6-8 days post-induction. Unless otherwise indicated, cells were rinsed
with PBS and media was changed to HEPES-buffered Krebs Ringer buffer (HKRB) + 1% BSA.
Where indicated, BAs were pretreated with triacsin C (5 µM; Sigma), BAY (5 µM), etomoxir (50
µM; Sigma), GW6471 (10 µM; Tocris), GSK0660 (2 µM; Tocris) or GW9662 (30 µM; Tocris),
followed by isoproterenol (10 µM, Sigma) or 8-Br-cAMP (1 mM, Biolog). For experiments
examining mitochondrial gene expression, BAs were stimulated for 24 h with 8-Br-cAMP (1
mM) or selective agonists of PPARα (GW7647, 1 µM; Tocris), or PPARδ (L-165,041, 5 µM;
Tocris).

2.3

Liquid chromatography–mass spectrometry (LC-MS)/MS quantification of ceramides
and sphingolipids
3T3-L1 adipocytes were stimulated with isoproterenol for 3 h, and cell pellets and culture

media were collected and processed for lipids quantification by LC/MS technique. Reverse
phase HPLC was performed using BDS HYPERSIL C8 columns (Thermo Scientific) and gradient
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elution on Waters Alliance 2695 system (Waters Corporation). The mobile phase consisted of
methanol, water, and ammonium formate. Solvent A was 2 mM ammonium formate in
methanol with 0.2% formic acid. The column was equilibrated with solvent A for 5 min.
Samples were injected using a Waters autosampler maintained at 10 ± 2oC. The injection
volumes were 80 µl for each sample. A complete injection of each sample took 7 min including
column equilibration, while the flow rate was 0.3 ml/min. The HPLC eluent was directly
injected into a QuattroLC mass spectrometer (Micromass-Waters, MA), equipped with an
electrospray ion (ESI) source that was used for ESI–MS/MS. The ESI–MS/MS experiments for
the quantification of sphingolipids were carried out in the positive ion mode with ESI needle
voltage, 2.8 kV; source block temperature, 120oC; desolvation temperature, 350oC; desolvation
gas flow, 540 l/h; nebulizer gas flow, 80 l/h; and the collision gas pressure was 3.2×10−4 bar.
Cone voltage and collision energy for each multiple reaction monitoring (MRM) transition were
optimized.

Chromatographic data were analyzed by Quanlynx module of the Masslynx

software (Waters Corporation, MA) to integrate the chromatograms for each MRM transition.

2.4

cAMP measurements
For measurement of cAMP, 3T3-L1 adipocytes were pretreated with BAY or triacsin C

and stimulated for 10 min with isoproterenol. Cells were lysed with 0.1 M HCl, 0.2% Triton-X100. Acidified cell lysates were collected and neutralized with NaOH and centrifuged at 1000×g
for 10 min and the supernatant was collected. The cAMP levels were quantified by ELISA
(Biomedical Technologies) as suggested by the manufacturer.
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2.5

siRNA knockdowns
Knockdown of ATGL in 3T3-L1 adipocytes was performed using small interfering RNA

(siRNA), as previously described (Kilroy, Burk, and Floyd 2009).

Briefly, adipocytes were

trypsinized and replated (1.8 × 105 cells/well) in collagen-coated 24-well plates containing 100
nM siRNA against ATGL (siATGL; Dharmacon M-040220-01) or non-targeting siRNA (siCON;
Dharmacon D-001210-01). At 72 h post-transfection, media was changed and cells were
stimulated with 10 µM isoproterenol for 3 h in triplicate per group.
siRNA knockdown in BAs was performed on cultures four days post-induction. Cells
were trypsinized and replated (2.4 × 105 cells/well) in collagen-coated 24-well plates containing
Lipofectamine 2000 (Invitrogen) and 50 nM of SMARTpool siRNA (Dharmacon) against PPARα
(siPPARα; M-040740-01-0005), PPARδ (siPPARδ; M-042751-01-0005) or non-targeting siRNA
(siCON; D-001210-01). Experiments were performed 72 h post-transfection on triplicate wells.

2.6

Lentivirus transduction
Undifferentiated BAs were infected with lentivirus vectors (Open Biosystems) for a

control non-targeting shRNA (RHS4346; shCON) or one directed against ATGL (RMM443198739845; shATGL) at a multiplicity of infection of 100 for 24 h, and selected by hygromycin
(GoldBio, 4 µg/ml) for 1 week followed by GFP fluorescence by FACS. Cells were differentiated
and treated as above.
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2.7

Reporter assays
cAMP response element (CRE) reporter assays were performed using a cAMP responsive

reporter plasmid (pADneo2 C6-BGL) provided by Dr. Adolf Himmler (Himmler, Stratowa, and
Czernilofsky 1993).

Five days after induction of differentiation, 3T3-L1 adipocytes were

trypsinized and replated (3.6 × 105 cells/well) in collagen-coated 12-well plates containing
media and 2 µg of pADneo2 C6-BGL, 0.08 µg of β-galactosidase (β-gal) and 4 µl Lipofectamine
2000 (Invitrogen). On the following day, transfection media was changed to DMEM containing
0.1% BSA, and cells were treated in duplicate with BAY (5 µM), triacsin C (5 µM) or DMSO for 30
min, followed by treatment with FSK (10 µM) for 6 h. Cells were harvested in 150 µl of Cell
Culture Lysis Reagent (Promega) and 20 µl was assayed in duplicate. Luciferase activity was
measured in Luciferase Assay Buffer (15mM KH2PO4, 15mM MgSO4, 4mM EDTA, 2mM ATP,
1mM dithiothreitol) with 15 µg of D-Luciferin (Gold Biotechnology) using a MicroLumatPlus
LB96V luminometer (Berthold Technologies). β-gal activity was measured in 100 mM sodium
phosphate buffer pH 7.3, 1 mM MgCl2, 50 mM β-mercaptoethanol with ONPG (o-nitrophenyl-βD-galactopyranoside) at 420 nm (Versamax; Molecular Devices).

Luciferase activity was

normalized to β-gal and 4 separate experiments were analyzed by two-way ANOVA. Results are
reported as fold of FSK.
Gal4 luciferase reporter assays were performed by transfecting BAs with 0.7 µg of Gal4PPARα or Gal4-PPARδ, 0.7 µg of luciferase reporter (pUAS-Luc2; Addgene # 24343) and 100 ng
of β-gal reporter, as stated above. Cells were cultured on 12 well collagen-coated plates and
used 6-7 days post-differentiation. Transfected cells were treated with BAY or DMSO for 30 min
followed by Iso for 8 h, and lysed in 120 µl of Cell Culture Lysis Reagent (Promega). Ligands for
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PPARα (Wy) and δ (L165) were used as positive controls. Luciferase assays were performed as
described above and expressed as a % Iso.

2.8

Generation of reporter constructs
The ligand binding domain of human PPARα (NP_001001928; amino acid [a.a] 191-467),

mouse PPARα (NP_035274; a.a 191-469) PPARδ (NP_035275; a.a. 162-441) and PPARγ
(NP_001120802; a.a 207-474) were amplified by PCR. Ligand binding domains were cloned into
AgeI/NotI on the C-terminus of full length Plin1 (NP_783571). The LxxLL containing domain of
steroid receptor co-activator 1 (SRC1) (NP_035011; a.a. 620-770) was amplified from mouse
cDNA and cloned in-frame into enhanced yellow fluorescent protein (EYFP)-C1 (Clontech)
vector (EYFP-SRC1). Chimeras for the yeast GAL4 DNA-binding domain (DBD) were made by
fusing the DBD of GAL4 (a.a 1-147) in frame with the ligand binding domain of human PPARα
(a.a 167-468) or human PPARδ (NP_006229; a.a 139-441) into pcDNA3 (Invitrogen).

2.9

Live cell imaging
Fluorescent reporter experiments were performed by transfecting BAs with reporter

plasmids for PPARα, or δ, or γ and EYFP-SRC1 with Lipofectamine LTX/Plus (Invitrogen), as
recommended by the manufacturer. Cultures at 4-5 days post-induction were trypsinized, and
seeded onto 25-mm coverslips containing a mixture of DNA, LTX/Plus and DMEM + 10% FBS.
Images were acquired as previously described for EYFP fluorescence using a 40x 0.9NA water
immersion lens (Granneman et al. 2009). Images for EYFP and phase contrast were acquired
every minute and the region of interest (ROI) from an average of two frames was quantified
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using IPlabs software (Scanalytics). Cells were pretreated with DMSO or BAY for 10 min and the
basal fluorescence was recorded for 4-6 frames, followed by stimulation with 8-Br-cAMP (1mM)
for 20 min, and finally by the addition of ligands for PPARα (Wy 14,643 (Wy); 100 µM), PPARδ
(L-165,041 (L165); 10 µM) or PPARγ (Rosiglitazone [Rosi]; 10 µM) for 8-12 min. The data from
the ROI was normalized to the maximum EYFP fluorescence in the ROI induced by Wy, L165 or
Rosi. The effect of oleic acid (OA) on fluorescent reporters was tested with 400 µM OA,
complexed to BSA, for 12 min. Data was normalized to the maximal effect induced by full PPAR
agonists (Intrinsic Activity, IA), determined at the end of each experiment. Normalized data
from 3-4 independent experiments with 2-4 coverslips per experiment were combined for
presentation and statistical analysis. At the end of some experiments, coverslips were stained
for neutral lipids with LipidTOX Deep Red (Invitrogen) and imaged with rhodamine
excitation/emission filters (Granneman et al. 2009).

2.10

Quantification of cellular FFAs
Cellular FFA levels were quantified by briefly rinsing cells in 12 well plates once with

DMEM containing 0.1% BSA, followed by two washes in PBS. Cellular FFAs were then extracted
by adding 500 µl of Dole reagent (isopropanol/n-heptane/1N sulphuric acid: 40:10:1) and
incubating for 10 min. Extractions were then transferred to 12x75 mm glass tubes and 200 µl of
n-heptane followed by 300 µl of water was added.

Samples were briefly vortexed and

centrifuged at 1000 g for 5 min. 200 µl (62.5%) of the upper organic layer was then transferred
to a new glass tube and samples were dried with a gentle stream of nitrogen gas while heating
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at 40 C. Samples were then vortexed and resuspended in 110 µl of DMEM with 1% BSA and
quantified as described below for FFAs.

2.11

Quantification of FFAs and glycerol by biochemical methods

FFA released into medium were quantified using a NEFA-HR(2) kit (Wako Chemicals, USA) as
suggested by the manufacturer. Glycerol levels were quantified using Glycerol Reagent (SigmaAldrich) and both assays were read on a Versamax microplate reader (Molecular Devices).

2.12

RNA extraction and gene expression analysis
For analysis of mRNA, RNA from adipose was extracted in Trizol (Invitrogen) and then

purified with an RNeasy mini kit (Qiagen). RNA from 3T3-L1 adipocytes and BAs was isolated
using a Nucleospin RNA II kit (Macherey-Nagel). The expression pattern of various genes was
quantified by qRT-PCR analysis, as previously described (Mottillo, Shen, and Granneman 2007).
Briefly, RNA (0.5–1.0 μg) was reverse transcribed into cDNA by using Superscript II or
Superscript III (Invitrogen) and oligo(dT) primers as recommended by the manufacturer. Thirty
to fifty ng of cDNA was analyzed in a 20 µl quantitative PCR reaction (ABsolute Blue QPCR SYBR;
ThermoScientific) with 80 nM of primers. Expression data were normalized to the housekeeping gene peptidyl-prolyl cis-trans isomerase A (PPIA) using the delta-delta CT method (2ΔΔCT

)(Livak and Schmittgen 2001).

PPARα cDNA was amplified using forward and reverse

primers 5′-CTAACCTTGGGCCACACCT-3 and 5′ -CGGGTAACCTCGAAGTCTGA-3′, respectively. IL-6
cDNA was amplified using forward and reverse primers 5’-AGTGGCTAAGGACCAAGACC-3; and
5’-TCTGACCACAGTGAGGAATG-’3, PAI-1 cDNA were quantified with 5’-CCTCTTCATGGGCCAAGT-
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3’ and 5’-GGTAAGGAGGAGTTGCCTTC -3.

PDK4 cDNA was amplified using primers 5’-

AGGATTACTGACCGCCTCTT-3’ (forward) and 5’-CGTCTGTCCCATAACCTGAC-3’ (reverse), MCAD
with 5’-ATTGCCAATCAGCTAGCCAC-3’ (forward) and 5’-CTGATAGATCTTGGCGTCCC-3’ (reverse),
COXII with 5’-CGAGTCGTTCTGCCAATAGA-3’ (forward) and 5’-TCAGAGCATTGGCCATAGAA -3’
(reverse),

Cycs

with

5’-GGAGAAAGGGCAGACCTAAT-3’

(forward)

and

5’-

CTGTCCAACAAAAACATTGCT-3’ (reverse)and COXIV with 5’-CCCTCATACTTTCGATCGTG -3’
(forward) and 5’- TTATTAGCATGGACCATTGGA -3’ (reverse). The mRNA knockdown of PPARα
was

detected

with

primer

CGAATTGCATTGTGTGACAT-3’

5’-AGGCTGTAAGGGCTTCTTTC-3’

(reverse),

and

knockdown

of

(forward)

and

5’-

PPARδ

with

5’-

GACAATCCGCATGAAGCTC-3’ (forward) and 5’-GGATAGCGTTGTGCGACAT-3’(reverse). All other
cDNAs were amplified using primers previously described (Granneman et al. 2005, Li et al.
2005, Mottillo, Shen, and Granneman 2007, Mottillo and Granneman 2011).

2.13

Protein isolation and western blot analysis
Proteins were extracted in RIPA lysis buffer (25mM Tris pH 7.5, 150 mM NaCl, 1% Triton-

X-100, 0.5%, Na-deoxycholate, 1% NP-40, 0.5% sodium dodecyl sulfate, and 1mM EDTA)
containing protease inhibitors (Roche) and phosphatase (Pierce) inhibitors.

Lysates were

solubilized for 15 min at 4°C and centrifuged at 16,000 × g for 10 min to clear lysate. The
extracts were recovered and proteins were quantified by using the bicinchoninic acid method
(Pierce). Adipose tissue was homogenized in RIPA lysis buffer (20mM Tris, 150 mM NaCL, 1%
NP-40, 0.5% sodium deoxycholate, 1% SDS, 1mM EDTA) with inhibitors and treated as above.
50 μg of total protein was loaded on 10% mini-gels (Pierce) and SDS-PAGE was performed
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under reducing conditions. Resolved proteins were transferred to PVDF and membranes were
immunoblocked for 1 hr at room temperature in 5% powdered skim milk. Western blot was
performed using antibodies against ATGL (Granneman et al. 2011), HSL (provided by Dr. A.
Chaudhry) , and GAPDH (Millipore) as described (Mottillo, Shen, and Granneman 2007). Blots
were then washed, incubated with a secondary donkey anti-rabbit HRP (Jackson
immunological) diluted 1:5000, and visualized with SuperSignal West Dura substrate (Pierce).
Digital images were captured to ensure that pixels were not over-saturated using a BioRad
Quantity One imaging system.

2.14

Quantification of mitochondrial DNA content
Mitochondrial DNA was quantified on brown adipocytes that were stimulated with 8-Br-

cAMP, as stated above. DNA was extracted with phenol-chloroform-isoamylalcohol and QPCR
was performed using ABsolute Blue QPCR SYBR (ThermoScientific) for primers of Ndfuv1
(nuclear DNA, nDNA) and COXI (mitochondrial DNA, mtDNA), as described (Guo et al. 2009).

2.15

Measurement of mitochondrial respiration
Mitochondrial respiration was measured in digitonin permeabilized cells using the

Mitoxpress (Luxcell) phosphorescent oxygen sensitive fluorescent probe (Jonckheere et al.
2010, Kuznetsov et al. 2008, Will et al. 2007). Probe fluorescence is quenched in the presence
of molecular oxygen via a non-chemical (collisional) mechanism and is fully reversible. As cells
respire the change in oxygen consumption is seen as an increase in probe fluorescence and
reflects increase in mitochondrial activity over time (Will et al. 2007). shCON or shATGL BAs
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were stimulated with 1 mM 8-Br-cAMP for 48 h with media changed every 24 h. Cells were
trypsinized, washed once with PBS + 1 mM EDTA, followed by PBS + 1 mM EDTA + 1% BSA, and
resuspended in 250 µl of Respiration Buffer B (Modified from (Kuznetsov et al. 2008); 0.5 mM
EGTA, 5 mM MgCl2, 20 mM Taurine, 10 mM KH2PO4, 20 mM Hepes, 0.1 % BSA, 60 mM KCl, 110
mM Mannitol, pH 7.1). Cells were added to duplicate wells in a black clear bottom 96-well
plate containing 110 µl of Respiration Buffer B plus 20 µg/ml digitonin, 100 nM Mitoxpress
probe, 5 mM malate, and the indicated substrates (5 mM pyruvate, or 50 µM palmitoylcarnitine, with 2 mM ADP or 10 µM carbonylcyanide-p-trifluoromethoxyphenylhydrazone
(FCCP). The plate was covered with 100 µl of mineral oil to prevent diffusion of ambient oxygen
and wells read with a Molecular Devices SpectraMax M5 plate reader in time-resolved mode
(30 °C every 1.5 min, with an excitation/emission spectra of 380/650 nm, delay of 50 µs and a
gate time of 200 µs). No oxygen consumption was observed in cells without substrate or in
cells treated with substrate and 1 µM rotenone. Relative Oxygen Consumption Rate (ROCR)
was calculated as the maximal linear increase in fluorescence over 4.5 min (SoftMax Pro,
Molecular Devices) and normalized to 4×105 cells.

2.16

Statistical analysis
Unless stated otherwise, results are expressed as means ±SEM from a minimum of three

independent experiments.

Statistical analyses were performed with GraphPad Prism 5

(GraphPad Software) using one-way or two-way ANOVA. Planned post-hoc comparisons for
one-way or two-way ANOVA were performed using Bonferroni post t-test (equal variances) or
Dunn’s multiple comparison test (unequal variances), as indicated in the legends.
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Chapter 3. Intracellular fatty acids promote the expression of inflammatory
cytokines in white adipocytes
3.1

Expression of inflammatory cytokines by β-AR activation is mediated by intracellular

fatty acids
Our earlier work demonstrated that WAT inflammation induced by β3-AR agonist
treatment is mediated by HSL activity. HSL is an adipocyte lipase that acts on DAG as its
substrate, and is responsible for liberating up to 60% of FFAs in response to PKA activation
(Kraemer and Shen 2002). HSL is required for the initial expression of inflammatory cytokines
and subsequent recruitment of myeloid cells (Mottillo, Shen, and Granneman 2007). We
suspected that HSL mediates inflammation by releasing FAs; however inflammation produced
by β3-AR activation does not involve the putative extracellular saturated FA receptor, TLR4. To
explore alternate mechanisms, we asked whether the expression of inflammatory cytokines
might occur by intracellular accumulation and signalling of FFAs. To address this question, BSA,
which is a serum factor that binds fatty acids, was systematically reduced in the media of
cultured 3T3-L1 adipocytes in order to limit FFA efflux and promote intracellular accumulation
(Vallano, Lee, and Sonenberg 1983).

Reducing the concentration of BSA in the media

systematically lowered extracellular FFA concentration while increasing intracellular FFA levels
(Figure 2A and 2B).

Lowering BSA greatly enhanced the expression of CCL2 and PAI-1.

Importantly the expression of cytokines was the highest when cellular FFAs were the greatest
(i.e.no BSA present) (Figure 2C). We also tested the effect of HSL on cytokine expression with
BAY, a highly selective inhibitor that does not inhibit the other adipocyte TAG lipase, ATGL, and
has no effect in HSL-null mice (Mottillo, Shen, and Granneman 2007).

The increase in
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intracellular FAs and the subsequent induction of CCL2 and PAI-1 was completely abolished by
inhibition of HSL (Figure 2C), further supporting our initial finding that HSL regulates the
expression of inflammatory cytokines in adipocytes (Mottillo, Shen, and Granneman 2007).

Figure 2. Intracellular FFAs promote the induction of CCL2 and PAI-1 by β-AR activation.
A), 3T3-L1 adipocytes were incubated in decreasing concentration of BSA, pretreated with
BAY and treated with Iso for one hour. B), cells from A) were washed once with 0.1% BSA,
washed twice with PBS and fatty acids were extracted and quantified. Data shown are from
three separate experiments. One-way ANOVA was performed with post t-test to indicate
significance among indicated comparisons (** P<0.01, *** P<0.001). C), 3T3-L1 adipocytes
were incubated in indicated concentrations of BSA, and pretreated with BAY or vehicle for 1
hr, followed by Iso (10 uM) for 3 hr, and mRNA was analyzed for expression of indicated
genes by normalizing to % Control (Ctl). Statistical significance is shown for comparisons of
Ctl with different BSA concentrations (*** P<0.001; ** P<0.01).
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3.2

The induction of PAI-1 is partly mediated by ceramides/sphingolipids
The above results strongly indicate that intracellular FFA or FFA-derived metabolites

trigger adipocyte inflammation. To explore the possibility that downstream metabolites might
mediate FA-dependent inflammatory cytokines expression, we tested the role of
ceramides/sphingolipids, which are potential mediators in adipose tissue inflammation (Kolak
et al. 2007, Samad et al. 2006). We first examined whether β-AR stimulation increases the
production of ceramides and sphingolipids in 3T3-L1 adipocytes by performing LC-MS/MS
quantification. Stimulation of 3T3-L1 cells with isoproterenol elevated the production of
various species of ceramides and sphingolipids (Figure 3A). These bioactive signalling lipids can
be generated de novo from palmitic acid by the rate limiting enzyme serine
palmitoyltransferase (SPT).

Thus, to test the potential involvement of de novo

ceramides/sphingolipids in the induction of inflammatory cytokines expression, we examined
the effects of myriocin, a selective inhibitor of SPT (Miyake et al. 1995). Treatment of 3T3-L1
adipocytes with myriocin significantly reduced the expression of PAI-1 after β-AR activation, but
did not affect basal levels of gene expression (Figure 3B). Myriocin did not reduce IL-6 levels,
suggesting that de novo ceramides are not involved in the regulation of this cytokine and that
alternate pathways are involved (Figure 3C). Treatment with myriocin did not affect lipolysis,
demonstrating that the effects of SPT inhibition are not due to alteration in FFA mobilization
(Figure 3D). These results indicate that intracellular accumulation of FFAs and subsequent
generation of ceramides (and/or sphingolipids) contributes to the induction of PAI-1 by β-AR
activation.
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Figure 3. The induction of PAI-1 is partly
mediated by de novo ceramides/sphingolipids.
A), sphingolipids and ceramides were quantified
in 3T3-L1 adipocytes after stimulation with Iso
(10 µM) for 3hr. B,C), 3T3-L1 adipocytes were
pretreated with the SPT inhibitor myriocin (10
µM) for 1hr, followed by Iso treatment for 3h,
and mRNA was analyzed for the expression of
PAI-1 (B) and IL-6 (C). The effect of myriocin on
the induction of PAI-1 and IL-6 is shown (*
P<0.05; ns, non-significant). D), Myriocin does
not affect lipolysis. Media samples were
quantified for FFA and glycerol (*** P<0.001; **
P<0.01).
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3.3

Chapter 3 Discussion
Mounting evidence indicates that disrupting the balance between FA storage and

mobilization in adipose tissue contributes to local and systemic inflammation (Arion Kennedy et
al. 2009), and is likely to play a role in obesity-induced inflammation (Adilson Guilherme et al.
2008). Central to this is the dysfunctional metabolism of FFAs that leads to the formation of
secondary lipid mediators that are causative in insulin resistance (A. Kennedy et al. 2009, Li,
Klett, and Coleman 2010). We found that increasing intracellular FFAs enhanced the expression
of inflammatory cytokines in adipocytes and this was partly mediated by ceramides. These
results support the concept that adipocytes are a source of inflammatory cytokines and that
lipid flux in adipocytes toward intracellular FFAs promotes inflammation (Boden 2006, Kolak et
al. 2007). Increased ceramides in adipose tissue are associated with fatty liver, greater PAI-1
expression (Kolak et al. 2007), and insulin resistance in humans (Blachnio-Zabielska et al. 2012,
Samad et al. 2011).

Moreover, altering ceramide metabolism reduces the expression of

inflammatory cytokines in adipose tissue and improves whole body glucose tolerance
(Mitsutake et al. 2012). Our results indicate that tightly controlling the pool of intracellular
FFAs production might be beneficial.
Genetic mouse model that have elevated adipocyte lipolysis suggest that the
mobilization of FFAs is not detrimental as long as there is a counter response to upregulate
fatty acid oxidation (Cummings et al. 1996, Nishino et al. 2008, Tansey et al. 2001) (See Chapter
5).

In agreement, chronic activation of β3-AR enhances the ability to burn lipid, which

eventually limits inflammation and improves insulin action (Grujic et al. 1997, Li et al. 2005).
On the other hand, enhancing the storage capacity of WAT can also limit the detrimental
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effects of FFAs (Kim et al. 2007). In summary work presented in this chapter suggest that
preventing the accumulation of intracellular FAs by enhancing lipid oxidation or storage into TG
can prevent lipotoxicity in adipocytes.
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Chapter 4. Intracellular fatty acids limit the induction of oxidative genes in WAT
4.1

Inhibition of HSL potentiates β3-AR gene expression in WAT
The induction of inflammatory cytokines by β-AR activation in adipocytes is mediated by

intracellular FAs (Chapter 3), suggesting that the excessive mobilization of FFAs are detrimental
to fat cells and that internal restrains might exist to limit lipolysis. Activation of the β-AR/PKA
also promotes the transcription of genes that promote a thermogenic program in WAT such as
PGC1α, UCP1 and neuron-derived orphan receptor-1 (NOR-1) (Kumar et al. 2008, Pearen and
Muscat 2010). NOR-1 is a PKA-responsive orphan nuclear receptor that is a regulator of UCP1
expression in adipocytes and is highly responsive to β-adrenergic stimulation (Kumar et al.
2008). The objective of this chapter was to explore the relationship between lipolysis, gene
transcription and oxidative metabolism in white adipocytes.
The role of lipolysis in regulating the expression of oxidative genes by β3-AR activation
was first explored by pharmacological inhibition of HSL. We first examined the effect of
lipolysis on the expression of PGC1α and UCP1 and NOR-1 mRNA. As expected, treatment of
mice with the β3-AR agonist CL for 3 h elevated the expression of PGC1α, UCP1 and NOR-1 in
epididymal WAT. Pretreatment of mice with the HSL inhibitor BAY greatly enhanced CLmediated expression of PGC1α, UCP1 and NOR-1 by greater than five-fold. Importantly, HSL
inhibition did not modify basal levels of gene expression thereby demonstrating an interaction
effect of BAY on CL (Figure 4A). We also evaluated whether BAY affected expression of key
adipocyte transcription factors, which might account for BAY potentiating the expression of β3AR target genes. CL elevated expression of CCAAT/enhancer-binding protein β (C/EBPβ), and
this effect was not modified by HSL inhibition. CL reduced the expression of PPARγ and BAY did
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not have any effect. CL did not modify the expression of PPARα, nor did HSL inhibition. As
expected serum FAs and glycerol levels were elevated by β3-AR activation after challenging
mice with CL for 45 min (Figure 4B). Levels of both FFA and glycerol were suppressed by HSL
inhibition (Figure 4B). There was no effect of BAY on basal lipolysis in the mice. These results
suggest that HSL activity limits the expression of oxidative genes in WAT. Of importance is that
these genes (PGC1α and UCP1 and NOR-1) are also known direct PKA targets.
To further investigate whether lipolysis limits the expression of oxidative genes in vivo,
we evaluated the role of HSL by measuring the expression of PGC1α, UCP1 and NOR-1 in EWAT
of HSL-KO mice. Treatment of mice with CL for 6 h upregulated the expression of PGC1α and
NOR-1 in wild type mice, and this induction was significantly greater in HSL-KO mice (Figure 4C).
The effect of CL on UCP1 expression was not statistical significance (P=0.09) and the effect of
BAY on potentiating UCP1 expression was variable (P=0.1762). These results further support
the notion that HSL limits the expression of oxidative (PKA-targeted) genes in WAT and argues
against any off-target effects for the HSL inhibitor.
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Figure 4. Reducing lipolysis by inhibition or genetic deletion of HSL potentiates PKAtargeted genes during β3-AR activation in white adipose tissue of mice. A) Mice were
pretreated with BAY or methylcellulose (MC) for 1h, followed by CL treatment (10 nmol) or
vehicle (H2O) for 3 h and EWAT was collected and analyzed for mRNA expression by qPCR.
Data are from 8 mice per group and the effect of BAY is indicated (***=P<0.001; **=P<0.01;
ns, non-significant). B) Serum fatty acid and glycerol levels in mice treated with BAY or MC
followed by CL (10 nmol) for 45 min. The effect of BAY is indicated (***=P<0.001). C) mRNA
levels from EWAT of wild type (WT) and HSL knockout mice (HSL-KO) (n=3-7) were measured
by qPCR and normalized to % PPIA. The difference between WT and HSL-KO is indicated
(*=P<0.05).
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4.2

Limiting lipolysis potentiates β-AR induction of PKA-targeted genes in 3T3-L1

adipocytes
The above experiments suggest that the mobilization of FFAs acutely limit β3-AR
signalling in EWAT of mice and as a consequence the expression of oxidative genes. Since
adipose tissue consists of numerous cells including adipocytes, adipocyte progenitors, vascular
cells and macrophages, 3T3-L1 adipocytes were used as an in vitro cell culture model to test
whether lipolysis can directly modify gene expression in a cell autonomous manner. Cultured
3T3-L1 adipocytes were treated with the general β-AR agonist isoproterenol, which elevated
the mRNA levels of PGC1α, UCP1 and NOR-1 (Figure 5). HSL inhibition did not have any effect
on basal gene expression; however BAY potentiated the induction of PGC1α, UCP1 and NOR-1
by Isoproterenol. These results demonstrate that FA limit β3-AR signalling in a cell autonomous
intracellular manner.

We further utilized 3T3-L1 adipocytes as a model to explore the

relationship between lipolysis and oxidative gene expression.

Figure 5. Inhibition of HSL in 3T3-L1 adipocytes potentiates β-AR induction of PKAtargeted genes. A) 3T3-L1 adipocytes were treated with BAY or vehicle (DMSO) followed by
10 µM isoproterenol (Iso) or water (H2O) for 3 h. Gene expression was measured by qPCR
and normalized to % PPIA. Data are from five separate experiments and the effect of BAY is
indicated (***=P<0.001; *=P<0.05).
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In addition to HSL, adipocytes contain ATGL, the rate limiting enzyme for lipolysis
(Eichmann et al. 2012). As HSL is a major DAG lipase (Kraemer and Shen 2002) and ratelimiting for degradation of DAG, this raises the possibility that accumulation of DAG
(Haemmerle et al. 2002) might promote PKA-mediated gene expression rather than FA
inhibition. Thus, as an additional test that FFAs inhibit β-AR signalling and to eliminate the
possibility that DAGs potentiate gene expression, we performed siRNA knockdown of ATGL, the
rate limiting enzyme for PKA-mediated DAG production in adipocytes. Treatment of 3T3-L1
adipocyte with ATGL directed siRNA directed against ATGL (siATGL), greatly reduced ATGL
protein to almost undetectable levels as indicated by Western blot (Figure 6A). There was no
effect on protein levels of HSL, indicating that siRNA treatment did not affect the differentiation
of cells (Figure 6A). As expected, knockdown of ATGL reduces basal levels of FFA and glycerol
and abolished isoproterenol-induced lipolysis (Figure 6B).

There was no effect of ATGL

knockdown on basal gene expression, however isoproterenol induction of PGC1α, UCP1 and
NOR-1 was greatly potentiated in siATGL treated cells when compared to siCON treated cells
(Figure 6C). Overall, these results strongly indicate that FFAs mobilized by either ATGL or HSL
limit the induction of PKA-targeted genes by β-AR activation in adipocytes.
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Figure 6. Knockdown of ATGL potentiates β-AR induction of PKA-targeted genes. A)
Western blot for ATGL, HSL and GAPDH from three separate wells per siRNA. GAPDH serves
as a loading control. B) Glycerol and FFA levels from basal and stimulated (10 µM) siCON
and siATGL adipocytes. The effect of ATGL knockdown (siATGL) is indicated (***=P<0.001).
C) siCON and siATGL treated adipocytes were stimulated for 3 h with 10 µM isoproterenol
(Iso) or water (H2O). Gene expression was measured by qPCR and normalized to % PPIA.
The effect of ATGL knockdown (siATGL) is indicated (***=P<0.001). Data are from 3
experiments performed in triplicate.
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4.3

Intracellular FAs reduce β-AR-coupled gene expression in 3T3-L1 adipocytes
The results from Chapter 3 indicate that accumulation of intracellular FAs produces

inflammation in white adipocytes. Thus, we next examined whether increasing intracellular FAs
could modify the induction of PKA-targets by β-AR activation by blocking FA re-esterification
with triacsin C. Triacsin C is an inhibitor of long-chain acyl-CoA synthetases (ACSLs), which
control the conversion of FFAs to acyl-CoA derivatives (Coleman et al. 2002). During adrenergic
activation FFAs are constantly re-esterified back into TAG (Leibel and Hirsch 1985) by ACSLs.
Treatment of cells with triacsin C did not have an effect on basal levels of PGC1α, UCP1 or NOR1 (Figure 7A), nor did it elevate basal cellular FFA levels (Figure 7B). As expected isoproterenol
elevated levels of PGC1α and UCP1, while triacsin C reduced the induction of PGC1α and UCP1
by β-AR (Figure 7A). The expression of NOR-1 was highly variable in these experiments and the
effect of triacsin C was not statistically significant. Importantly, triacsin C elevated intracellular
FA levels under condition of β-AR activation (Figure 7B). These results suggest that intracellular
FFAs limit the induction of PKA targets by β-AR activation. In addition, it argues against the
involvement of fatty-acyl-CoAs since their production would be inhibited by triacsin C
treatment.
As an addition test, intracellular FAs were increased by limiting efflux by reducing BSA in
the medium of cultured 3T3-L1 adipocytes (see Chapter 3, Figure 2). The removal of BSA
suppressed the induction of PGC1α and UCP1 gene expression (Figure 7C). HSL inhibition
potentiated the induction of PGC1α and UCP1 under all conditions of BSA (Figure 7C). Of note,
is that BAY potentiated the expression of PGC1α (4.12 fold) and UCP1 (4.52 fold) the greatest
when intracellular FFAs were highest (0% BSA, see Chapter 3, Figure 2).
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Figure 7. Intracellular FAs suppress the expression of β-AR targeted genes. A) 3T3-L1
adipocytes were treated with 5 µM triacsin C or vehicle (DMSO), followed by 10 µM
isoproterenol (Iso) or water (H2O). Gene expression was measured by qPCR from seven
separate experiments and normalized to % PPIA. The effect of triacsin C is indicated
(**=P<0.01; ns, non significant). B) 3T3-L1 adipocytes were treated as in A), but Iso
treatment was for 1h. Intracellular FA were quantified, and statistical analysis was
performed by repeated measures ANOVA to determine the effect of triacsin C
(***=P<0.001). C) 3T3-L1 adipocytes were incubated in indicated concentrations of BSA, and
treated with BAY (5 µM) or DMSO, followed by Iso (10 µM) for 3 h. mRNA levels were
normalized to % PPIA and expressed as % Iso in the presence of 1 % BSA. One-way ANOVA
was performed to compare Iso with BAY/Iso at each BSA concentration (**=P<0.01;
***=P<0.001), and to test the effect of Iso at different concentrations of BSA (&=P<0.05;
&&&
=P<0.001). The fold difference between Iso and BAY/Iso is indicated above the bars.
Data are from three separate experiments performed in duplicate.
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4.4

FAs blunt β-AR induction of cAMP in 3T3-L1 adipocytes by inhibiting adenylyl

cyclase
PGC1α, UCP1 and NOR-1 are known cAMP/PKA targets in white adipocytes, so the next
logical step was to test whether FA mobilization limits cAMP production. As expected Iso
elevated intracellular cAMP levels in 3T3-L1 adipocytes (Figure 8A). Consistent with the effects
of BAY on potentiating gene expression, levels of cAMP were further increased by HSL
inhibition (Figure 8A). In contrast, treatment of cells with triacsin C, which reduced β-ARmediated induction of PGC1α and UCP1 (Figure 7A), decreased the production of cAMP by β-AR
(Figure 8B).
The above data are consistent with intracellular FFAs limiting the generation of cAMP
during β-AR stimulation, and this may explain the effect of HSL inhibition on gene expression.
We next wanted to localize the site within the β-AR/PKA cascade by which FA are inhibitory. To
accomplish this, we assessed the ability of BAY to potentiate gene expression at the level of AC
and at the level of cAMP/PKA. AC was directly activated with FSK and PKA was activated with
the cell permeable cAMP analogue 8-Br-cAMP. FSK increased the expression of PGC1α, UCP1
and NOR-1 similar to levels of Iso (Figure 8C). HSL inhibition potentiated the FSK-mediated
upregulation of PGC1α and UCP1, which indicates that FFAs inhibit the β-AR cascade, postreceptor. NOR-1 induction by forskolin was variable and the effect of BAY did not reach
statistical significance. 8-Br-cAMP elevated the levels of PGC1α, UCP1 and NOR-1 similarly to
that of FSK, but in contrast, BAY did not enhance gene expression by 8-Br-cAMP (Figure 8C).
These results indicate that FFAs inhibit gene expression upstream of PKA. Together, these
results point to FFAs inhibiting β-AR signalling at the level of AC.
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We next wanted to interrogate the transcriptional genetic elements by which FFAs
might limit expression of PKA-targeted genes. The promoters of the PGC1α, UCP1, and NOR-1
contain various response elements (Cao et al. 2004, Kumar et al. 2009, Rim and Kozak 2002) in
addition to cAMP response elements (CREs) that PKA signals through (Reusch, Colton, and
Klemm 2000).

To explore the role of FFAs on CRE-mediated transcriptional activity in

adipocytes, we used a luciferase reporter assay (Himmler, Stratowa, and Czernilofsky 1993). To
this end, 3T3-L1 adipocytes were transfected with the CRE luciferase reporter and subsequently
treated with FSK. We chose FSK in order attain maximal cAMP/PKA signalling. FSK greatly
elevated levels of the CRE luciferase reporter. BAY enhanced reporter activity, while treatment
with triacsin C reduced reporter activity (Figure 8D). There was no effect of BAY or triacsin C on
basal CRE reporter levels. Importantly, these data are consistent with both the effects of BAY
and tracsin C on PKA-mediated gene expression, and cAMP production. Overall these results
demonstrate that FFAs limit the expression of PKA-targeted genes by mitigating cAMP/CREmediated transcription activity.
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Figure 8. FAs suppress cAMP/PKA signalling at the level of AC. A) 3T3-L1 adipocytes were
treated with BAY, followed by Iso for 10 min. cAMP levels were measured from three
separate experiments each performed in duplicate. The effect of BAY is indicated
(*=P<0.05). B) 3T3-L1 adipocytes were treated with Triacsin C, followed by Iso for 10 min.
cAMP levels were measured in two separate experiments each performed in triplicate. The
effect of triacsin C is indicated (*=P<0.05). C) 3T3-L1 adipocytes were treated with vehicle
(DMSO) or BAY (5 µM) followed by FSK (4 µM) or 8-Br-cAMP (1 mM). mRNA levels were
measured by qPCR and normalized to % PPIA. The BAY effect is indicated (***=P<0.001;
*=P<0.05; ns, non-significant). D) 3T3-L1 adipocytes, transfected with a CRE reporter, were
treated with vehicle (DMSO), BAY or triacsin C, followed by FSK for 6 h. Reporter activity is
expressed as fold of FSK and statistical analysis was performed on the normalized data
(RLUs/β-gal OD) by repeated measures ANOVA to determine the effect of BAY
(***=P<0.001) or triacsin C (*=P<0.05).
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4.5

Limiting lipolysis increases mitochondrial activity and promotes CL-induced fat loss
The in vivo (4.1) and in vitro (4.2-4.4) data above indicate that lipolysis restrains cAMP

production and thereby limits induction of β-AR/PKA-targeted genes. We wanted to explore
the in vivo ramifications of this feedback pathway. We hypothesized that limiting lipolysis could
promote the browning of white fat and CL-mediated body fat loss. We choose a period of 5
days of CL treatment, during which the induction of oxidative genes and body fat loss are
maximal (Mottillo, Shen, and Granneman 2007). Mice were treated for 5 consecutive days with
CL or CL with HSL inhibition (BAY). As we have previously shown (Granneman et al. 2005, Li et
al. 2005), CL greatly elevated the expression of long chain acyl-CoA dehydrogenase (LCAD), a
marker of fat oxidation; the expression of cytochrome c oxidase subunit VIIIb (Cox8b), a
mitochondrial enzyme; and brown adipocyte markers UCP1 and elongation of very long chain
fatty acids-like 3 (Elovl3). Mice that were treated with BAY and CL had significantly greater
mRNA levels of LCAD, Cox8b and Elovl3, and levels trended to be greater for UCP1 (Figure 9A).
We also examined mitochondrial electron transport chain activity in adipose tissue explants. CL
tended to increase mitochondrial activity as measured by the reduction of TTC; however, this
effect was significant only within the BAY group (Figure 9B). Importantly we also measured
body fat in mice. Similarly, 5 days of CL treatment significantly reduced body fat only in mice
that had been treated with both CL and BAY (Figure 9C). There was no change in total body
weight of mice (Figure 9C). These results indicate that inhibiting HSL enhances the fat loss
effects of CL, which is likely driven by the increased browning effects that we observed in WAT.
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Figure 9. Partial inhibition of lipolysis enhances markers of white fat browning and
mitochondrial activity, and promotes fat loss in mice. Mice (n=8 per group) were treated
with BAY (30 mg/kg) or methylcellulose (MC) followed by CL (5D CL, 10 nmol) or saline
repeatedly for five days. A) mRNA levels in EWAT were measured by qPCR and normalized
to % PPIA. The effect of BAY on 5 day CL is shown (***=P<0.001; **=P<0.01). B) TTC
reduction as a measure of mitochondrial electron transport chain activity. The effect of 5D
CL treatment is shown (***=P<0.001; ns, non significant). C) Body fat composition was
measured in mice by MRI and expressed as loss of body fat. The effect of 5D CL is indicated
(**=P<0.01; ns, non-significant).
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4.6

Chapter 4 Discussion
The current results imply a negative feedback system whereby FAs limit cAMP

production at the level of AC. As a consequence, this feedback system limits the induction of
oxidative (PKA-target genes) in WAT (Figure 10A). FAs suppress cAMP production in cultured
adipocytes and in adipocyte membranes (Fain and Shepherd 1975, Ho et al. 1975); however,
the impact of this potential feedback on PKA-mediated gene expression and the in vivo effects
of β3-AR activation are not known. Our data indicate that FFAs limit cAMP production at levels
of β3-AR occupancy that are sub-maximal with respect to the induction of PKA-targeted genes.
Thus, inhibiting HSL relieves the negative feedback on AC, which allows for greater cAMP
production and increased expression of oxidative genes such as PGC1α and UCP1 (Figure 10B).
Inhibition of HSL dampens the relationship between cAMP production and lipolysis without
affecting the relationship between cAMP and oxidative gene expression, and thus provides a
better balance between FA mobilization and oxidation.

Consequently, inhibition of HSL

enhanced mitochondrial activity and weight loss associated with β3-AR agonist treatment.
While it seems contradictory that inhibition of HSL would promote greater oxidation and fat
loss, this can be explained by the presence and activation of ATGL. Of note, is that the EWAT of
HSL-KO mice attain a brown adipose tissue phenotype and are resistant to diet-induced obesity
(Strom et al. 2008). In a similar fashion, overexpression of ATGL in adipose tissue promotes
increased oxidative metabolism and greater weight loss in mice (Ahmadian et al. 2009).
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Figure 10. Limiting lipolysis promotes β3-AR signalling in WAT. A) Acute stimulation of the
β3-AR activates adenylyl cyclase (AC) and PKA and subsequently ATGL and HSL, and
transcription factors (TF) which promote the transcription of genes such as PCG1α, UCP1 and
NOR-1. The mobilization of FAs causes inflammation and feedback to reduce AC activity. B)
During inhibition of HSL in vivo, FA mobilization is reduced, inflammation is suppressed and
the negative feedback on AC is relieved, thereby increasing expression of PKA-targeted
genes and promoting fat loss.
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Metabolic remodelling of WAT by β3-AR is a dynamic process, and it is likely that
limiting lipolysis would facilitate the early, but not the late phases of remodelling (Granneman
et al. 2005, Li et al. 2005). In the early phase of β3-AR activation, adipose tissue has low
capability for lipid oxidation, and the mobilization of FAs triggers inflammation (Chapter 3), and
suppresses cAMP production. By limiting FAs during acute β3-AR activation, inflammation is
prevented (Chapter 3) and the transition to an oxidative phenotype is facilitated. In the late
phase, the capacity of WAT for lipid oxidation is enhanced, and FAs are not expected to
promote inflammation or limit PKA-targeted gene expression.

In agreement, we have

previously shown that the deleterious effects of mobilized FAs are mitigated once the oxidative
capacity of WAT has been expanded (Li et al. 2005). Thus, once WAT has been fully “browned”,
lipolysis could be fully reinstated to permit greater fat loss. In this case lipolysis in WAT would
be greater coupled to oxidation, similarly to that of BAT (Chapter 5).
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Chapter 5. Lipolytic products activate PPARα and δ in brown adipocytes to
match fatty acid oxidation with supply
5.1

Lipolysis is required for the maximal induction of thermogenic gene expression by βAR in brown adipocytes and BAT
FFAs are necessary and sufficient to drive thermogenesis in BAT. Based upon the role of

lipolysis in activating thermogenesis in brown fat and our previous work that lipolysis produces
inflammation and restricts cAMP generation in white adipocytes, we suspected that lipolysis
would have the opposite effects in modulating the expression of oxidative genes in BAT. We
initially tested the role of lipolysis in promoting gene expression in BAT by pharmacological
inhibition of HSL. Mice were first challenged with the β3-AR agonist CL 316,243 (CL) and the
expression of thermogenic genes in BAT was analyzed by qPCR. CL induced the expression of
PGC1α, PPARα, pyruvate dehydrogenase kinase 4 (PDK4), UCP1 and NOR-1 in BAT (Figure 11A),
while inhibition of HSL with BAY reduced the induction of PGC1α, PPARα, PDK4 and UCP1, but
not NOR-1. As an additional test of the in vivo role of HSL, we challenged WT/Het and HSL-KO
mice with CL. CL induced the expression of PGC1α, PPARα, PDK4, UCP1 and NOR-1 in WT/Het
mice and this effect was reduced in HSL-KO mice for PGC1α and UCP1 and trended to for
PPARα (P=0.058) and PDK4 (P=0.18) (Figure 11B). The induction of NOR-1 was similar between
WT/Het and HSL-KO mice. These results are in complete contrast to what we observed in white
fat, where HSL inhibition potentiated the expression of genes by β3-AR (Chapter 4).
Importantly, this suggests that different mechanisms are at work in modulating the induction of
genes by B3-AR in WAT vs. BAT.
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Figure 11. HSL is required for β3-AR mediated induction of thermogenic genes in BAT. A,
mice (n=11) were pretreated with BAY (30 mg/kg) or methylcellulose (MC) for 1 h, followed
by CL-316,243 (CL; 10 nmol) or vehicle (H2O) for 3 h and BAT was analyzed for mRNA
expression by QPCR and normalized to % PPIA. B, mice (n=13) WT, heterozygous (Het), or
deficient (KO) for HSL were treated with CL (10 nmol) for 6 h and BAT was analyzed for
mRNA as above. The effect of BAY (two-way ANOVA), or difference between WT/Het and
HSL-KO mice (two-way ANOVA) is indicated (**P < 0.01; *P < 0.05; n.s., non-significant).
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We next wanted to verify our in vivo finding in a cell culture model by using an
immortalized brown adipocyte cell line. Treatment of BAs with the β-AR agonist Iso similarly
induced the expression of PGC1α, PPARα, PDK4, and NOR-1 (Figure 12A). HSL inhibition (BAY)
did not have any effect on the basal levels of gene expression; however BAY reduced the
induction of PGC1α, PPARα, PDK4, but not NOR-1 by β-AR activation. As expected, lipolysis was
increased by β-AR, and reduced by BAY (Figure 12B). To ensure that these effects on gene
expression were not due to alterations at the level of the β-AR, we bypassed the β-AR by using
the cAMP analogue, 8-Br-cAMP. Stimulation of BAs with 8-Br-cAMP induced the expression of
PGC1α, PPARα, PDK4, and UCP1, and this effect was reduced by BAY (Figure 12C). Inhibition of
HSL did not have any effect on the induction of NOR-1 mRNA by 8-Br-cAMP. These results
suggest that HSL functions to promote the induction of a subset of genes by β-AR/PKA
activation in BAs. Importantly, many of the genes that are regulated in a HSL-dependent
manner are important in BAT thermogenesis.
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Figure 12. HSL is required for β-AR mediated induction of oxidative genes in brown
adipocytes. A, brown adipocytes were treated with BAY (5 µM) or vehicle (DMSO), followed
by isoproterenol (Iso; 10 µM) for 4 h. mRNA levels were measured by QPCR, normalized to
% PPIA and expressed as a % Iso. B, FFA in the media were measured after 4 h and
expressed as a fold of Iso. C, brown adipocytes were treated as in A, except cells were
stimulated with 8-Br-cAMP (1 mM). Data are from 3-4 independent experiments performed
in duplicate and analyzed by two-way ANOVA to determine the effect of BAY (***P < 0.001;
**P < 0.01; *P < 0.05; n.s., non-significant).
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Adipocytes also contain ATGL, which is the rate limiting enzyme for lipolysis. We tested
the role of ATGL in the upregulation of thermogenic genes by β-AR activation by making stable
cell lines that express a control shRNA (shCON) or shRNA against ATGL (shATGL). Brown
adipocyte cells expressing shATGL demonstrated reduced protein levels of ATGL (Figure 13A),
and a reduction in lipolysis under basal conditions and also with β-AR activation (Figure 13B).
Importantly, there was no observable difference in the ability of cells to differentiate as
determined by bright field microscopy (Figure 13C).

Treatment of shCON cells with Iso

promoted the expression of PGC1α, PPARα and PDK4, and this induction was lower in shATGL
cells (Figure 13D). The upregulation of NOR-1 by Iso was similar between shCON and shATGL
cells. Inhibition of HSL further diminished lipolysis in shATGL cells (Figure 13B) and resulted in
a further reduction is the expression of PGC1α and PPARα (Figure 13D).

The effect of HSL

inhibition on PDK4 mRNA in shATGL cells did not have any further effect as levels of PDK4 were
already greatly reduced (Figure 13D). BAY did not affect the expression of NOR-1. Together,
these results indicate that lipolysis via the concerted action of ATGL and HSL regulates the
expression of thermogenic genes by β-AR activation in BAs.
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Figure 13. Knockdown of ATGL reduces the induction of oxidative genes by β-AR activation
in brown adipocytes. A, western blot was performed on shCON and shATGL brown
adipocytes for ATGL and GAPDH. B, FFA in the media were measured after 4 h and
expressed as a fold of Iso. C, brightfield images of differentiated shCON and shATLG brown
adipocytes. D, shCON and shATGL brown adipocytes were treated with Iso (10 µM) or BAY
and Iso (BAY/Iso) for 4 h and mRNA levels were measured by QPCR, normalized to %PPIA
and expressed as a percent of shCON Iso. Data are from 3 separate experiments performed
in duplicate, and the difference between shCON and shATGL cells by two-way ANOVA is
indicated (***P < 0.001; n.s., non-significant).
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5.2

Increasing fatty acids promotes thermogenic gene transcription in brown adipocytes
The above results suggest that lipolytic products, which are likely FFAs, function to

positively regulate gene transcription in BAs. To further test the role of FFAs we performed
experiments to manipulate endogenous FA levels. First, fatty acids levels were modified by
blocking their oxidation via inhibition of carnitine palmitoyl-transferase 1 (CPT1), which is the
rate limiting step for entry of activated FAs into the mitochondria. Inhibition of CPT1 by
etomoxir in BA had no effect on the basal expression levels of PGC1α, PDK4, PPARα and UCP1.
However, etomoxir enhanced the induction of PGC1α, PDK4, PPARα and UCP1 by
Iso (Figure 14A). Etomoxir did not have any effect on efflux of FFAs into the media (Figure 14B).
Secondly, FFA levels were increased in brown adipocyte by inhibiting the activity of long chain
acyl-CoA synthetases (ACSLs) with Triacsin C. ACSLs are required to catalyze the formation of
fatty acyl-CoA from FFAs. Triacsin C elevated FFA levels (Figure 14C), which was sufficient to
promote the expression of PGC1α, PDK4, UCP1 and PPARα in the absence of PKA activation
(Figure 14D). These results demonstrate that endogenous FAs promote the expression of
thermogenic genes in BAs.
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Figure 14. Endogenous fatty acids increase the transcription of genes involved in
thermogenesis in brown adipocytes. A, brown adipocytes were treated with etomoxir (ETX;
50 µM) or vehicle (H2O) followed by Iso (10 µM) for 4 h. mRNA levels were measured by
QPCR, normalized to %PPIA and expressed as a percent of Iso. B, brown adipocytes were
treated with triacsin C or vehicle (DMSO) and FFA in the media were measured after 4 h and
expressed as nmol/hr. C, brown adipocytes were treated as in B, and mRNA levels were
quantified by QPCR and expressed as a fold of control (Ctl). Data are from 3-4 separate
experiments performed in duplicate, and the effect of ETX or triacsin C is shown (***P <
0.001; **P < 0.01; *P < 0.05).
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5.3

PPARα and PPARδ mediate the induction of thermogenic genes by β-AR activation
We next addressed the mechanisms of how lipolytic products increased thermogenic

gene expression in BAs. Common among the promoter regions of the PGC1α, PDK4 and UCP1
genes are binding sites for the family of nuclear receptor called PPARs, which consists of PPARα,
PPARδ and PPARγ. The PPARs regulate various aspect of lipid metabolism and are known to be
activated by various lipid species. First we tested the role of PPARs in regulating the expression
of thermogenic genes by β-AR by using selective antagonists (Figure 15A,C). Treatment of BAs
with antagonists against PPARα and δ significantly reduced the induction of gene expression
(Figure 15A). The PPARα antagonist GW6471 reduced the induction of PGC1α, PPARα, PDK4
and UCP1, while antagonism of PPARδ by GSK0660, reduced the upregulation of PPARα, PDK4
and UCP1 and not PGC1α. Neither the PPARα nor PPARδ antagonists had any effect on lipolysis
(Figure 15B). In contrast, the effect of PPARα and δ antagonists, there was no effect of the
PPARγ antagonist GW9662 on the induction of genes by β-AR agonism (Figure 15C).
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Figure 15. Antagonists against PPARα and δ, but not PPARγ reduce the induction of
thermogenic genes by β-AR activation in brown adipocytes. A, brown adipocytes were
treated with antagonists against PPARα (GW6741; 10 µM) or PPARδ (GSK0660; 2 µM)
followed by Iso (10 µM) for 4 h. mRNA levels were measured by qPCR, normalized to %PPIA
and expressed as a percent of Iso. Data are from 4 separate experiments performed in
duplicate, and the effect of GW6471 or GSK0660 by two-way ANOVA is shown (***P < 0.001;
**P < 0.01; *P < 0.05). B, FFA levels from A were measured in the medium and expressed as
nmol/hr. C, brown adipocytes were treated with PPARγ antagonist (GW9662, 30 µM)
followed by Iso for 4 h. The differences between groups were evaluated by one-way ANOVA
.

59
As pharmacological probes can have disadvantages with selectivity, we wanted to
further test the above results by performing siRNA knockdown of PPARα and PPARδ. Targeted
siRNAs effectively knocked down mRNA levels of PPARα and δ by greater than 60% (Figure
16A). Knockdown did not affect basal or Iso stimulated lipolysis as detect by efflux of FFAs into
the media (Figure 16B). Knockdown of PPARα (siPPARα) significantly reduced the induction of
PGC1α, PDK4, and UCP1 by Iso, but not NOR-1. siRNA against PPARδ (siPPARδ) reduced the
upregulation of PDK4 and UCP1 by isoproterenol (Figure 16C). PPARδ knockdown did not have
any effect on the induction of PGC1α or NOR-1 mRNA by isoproterenol. Importantly, that
knockdown of PPARα or PPARδ did not have any effect on lipolysis or the induction of NOR-1
mRNA, suggests that siRNA treatment did not have any effect on the differentiation of BAs. In
conjunction with the above antagonist studies, these results demonstrate that PPARα and δ are
required for the maximal induction of thermogenic genes by β-AR activation.
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Figure 16. Knockdown of PPARα and δ reduces the induction of thermogenic genes by βAR activation in brown adipocytes. A, mRNA levels of PPARα and δ in brown adipocytes
treated with control (siCON), PPARα (siPPARα), or PPARδ (siPPARδ) siRNA normalized to
%PPIA and expressed as a Fold of siCON. B, FFA levels in the medium from C were measured
at 1 h after stimulation and expressed as nmol/hr. C, siCON, siPPARα or siPPARδ treated
brown adipocytes were stimulated with Iso for 4 h, mRNA was quantified and expressed as a
percent of siCON Iso. Data are from 3 separate experiments performed in triplicate and the
effect of siPPARα or siPPARδ by two-way ANOVA is shown (***P < 0.001; n.s., non
significant). C,
5.4

Lipid droplets generate ligands that can transcriptionally activate PPAR α and δ, but

not PPARγ
The above results suggest that PPARα and δ detect lipolytic products. Thus, we
investigated whether lipolysis produced agonists for PPARs. PPARs are activated when agonists
enter the nucleus, bind their cognate receptor, and recruit co-activator molecules. While the
mechanisms of nuclear receptor activation are well known, the pathways that produce ligands
and their site of production are poorly understood. We tested whether lipid droplets generate
ligands for PPARs by developing a fluorescent reporter assay that is based upon the liganddependent interaction between PPARs and the transcriptional co-activator SRC-1. We fused
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the ligand binding domain (LBD) of PPARs to the lipid droplet protein Plin1, and the LxxLL
domain of SRC-1 to EYFP (Figure 17A). Therefore, if PPAR ligands are generated by lipolysis,
they would be detected by translocation of EYFP-SRC1 from the cytoplasm to the Plin1-PPAR
LBD fusion on the lipid droplet. In BAs co-transfected with the Plin1-PPARα fusion and EYFPSRC1, EYFP fluorescence was predominantly cytosolic under basal conditions (Figure 17B).
EYFP-SRC1 translocated to the lipid droplet surface within minutes after addition of 8-Br-cAMP,
and the intensity of fluorescence continued to increase for 20 min (Figure 17B, arrows). HSL
inhibition greatly reduced the recruitment of EYFP-SRC1 to lipid droplets (Figure 17B, arrows).
As a measure that the PPARα fluorescent reporter could be rescued with HSL inhibition, the
PPARα agonist, Wy 14,263, was added to fully stimulate reporter translocation to lipid droplets
(Figure 17B; Wy). By normalizing the data to the maximal effect induced by Wy, there was a
significant effect of HSL inhibition on the activation of the PPARα reporter (Figure 17C).
Similarly, stimulation of BAs with 8-Br-cAMP increased the activity of the PPARδ reporter, and
this effect was nearly abolished by BAY (Figure 17D). In contrast, 8-Br-cAMP did not promote
EYFP-SRC1 translocation to lipid droplet with PPARγ, but the reporter was fully activated with
the PPARγ ligand rosiglitazone (Figure 17E). We also found that activation of the PPARα
fluorescent reporter was lower in BAs with ATGL knockdown (Figure 17F). These results
suggest that ligands for PPARα and δ are generated by lipid droplets in response to lipolysis.
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Figure 17. Ligands for PPARα and δ, but not PPARγ are created at the lipid droplet surface
in response to lipolysis. A, schematic representation of constructs used for the fluorescent
reporter assays (amino acids for SRC-1 are shown). B, brown adipocytes transfected with a
PPARα reporter were pretreated with DMSO (Ctl) or BAY (5 µM) for 10 min. Representative
images shown prior to stimulation (-, t=0) with 1 mM 8-Br-cAMP, or after 20 min of
stimulation (+, t=20), and after addition of PPARα ligand (Wy 100 µM). C, the PPARα
reporter was quantified by normalizing the region of interest (ROI) after treatment with 8Br-cAMP or BAY/8-Br-cAMP to the maximal effect of Wyeth from 2-3 coverslips per
experiments (n=3). D, The PPARδ reporter was normalized to the maximal effect of L165,041 (L165, 10 µM). The effect of BAY was determine by unpaired t-test (***P < 0.001;
**P < 0.01). E, the PPARγ reporter was quantified by normalizing the ROI after 8-Br-cAMP to
the maximal effect of Rosi (10 µM). F, the PPARα reporter was quantified in shCON and
shATGL brown adipocytes after treatment with 8-Br-cAMP as above, and the difference was
determined by unpaired t-test (*P < 0.05).
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To verify that activated PPAR reporters were correctly targeted to lipid droplets, cells
were co-stained with a fluorescent neutral lipid dye, lipidTOX, and imaged for YFP fluorescence
(Figure 18). Arrows note where activated PPAR reporters localize to lipid droplets in the same
cells.

Figure 18. PPAR fluorescent reporters are correctly targeting to lipid droplets. Brown
adipocytes transfected with the different PPAR reporters were treated with respective
PPARs ligands, stained with LipidTOX and imaged for EYFP flouresecence (YFP) and neutral
lipids (TGs).

To further establish that FAs are ligands for PPARα and δ, the addition of exogenous FAs
was tested. Addition of oleic acid (OA), which is a major FA found in TGs, was sufficient to
activate PPARα and δ, but not γ, while addition of ligand fully activated the three reporters
(Figure 19A). Quantification of these results relative to intrinsic activity of ligand demonstrates
that 8-Br-cAMP activated PPARα and δ nearly as much exogenous OA (80%; Figure 19B).
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Figure 19. FAs are sufficient to activate PPARα and δ. Brown adipocytes transfected with
reporters for PPARα, δ and γ were treated with 400 µM OA and the data was normalized to
the Intrinsic Activity (IA) of the respective ligands Wy, L165 and Rosi.
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We also tested the role of lipolytic products in activating PPARα and δ transcription
using classical transcriptional reporter assays where the yeast Gal4 DNA binding domain is
fused to the ligand binding domain of PPARs.

As expected, β-AR stimulation induced

transcription of Gal4/PPARα and Gal4/PPARδ reporters, and this effect was reduced with HSL
inhibition (Figure 20). Overall, these results demonstrate that ligands for PPARα and δ are
generated at the lipid droplet surface and increase the transcriptional activity of PPAR α and δ.

Figure 20. Lipolysis stimulates PPARα and δ transcriptional activity. Brown adipocytes
transfected with β-galactosidase (β-gal), luciferase reporter and hPPARα-Gal4 or hPPARδGal4 fusions were treated with vehicle or BAY (5 µM) and stimulated with Iso (10 µM) for 8
h. Luciferase reporter activity was normalized to β-gal activity and expressed as a percent of
Iso, and statistical analysis was performed by one-way ANOVA to determine the effect of
BAY or Iso.
5.5

Knockdown of ATGL reduces PKA upregulation of mitochondrial gene expression and
fatty acid oxidation
The data thus far suggest that lipolytic products activate PPARα and δ to promote the

expression of thermogenic genes.

We wanted to test the functional significance of the

relationship between lipase and oxidative metabolism, so to this end we examined the role of
lipolysis in regulating mitochondrial gene expression and lipid oxidation. Activation of the β-AR
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in BAs is known to increase mitochondrial biogenesis (Nechad, Nedergaard, and Cannon 1987),
so we first tested whether direct activation of PPARα and δ was sufficient to promote
mitochondrial gene expression. Although basal levels of long chain acyl-CoA dehydrogenase
(LCAD) and medium chain acyl-CoA dehydrogenase (MCAD) mRNA were lower in shATGL BAs,
direct agonists of PPARα and δ elevated their expression to similar levels observed in shCON
cells (Figure 21A). Likewise, PPARα and δ agonists increased the expression of cytochrome C
(Cycs) and cytochrome C oxidase IV (COXIV) to similar levels in control and ATGL shRNA
expressing BAs (Figure 21A). These results demonstrate that activation of PPARα and δ is
sufficient

to

elevate

the

expression

of

mitochondrial

genes

involved

in

FA oxidation and oxidative phosphorylation. We next tested whether stimulation with cAMP
could increase the expression of mitochondrial genes equally in shCON and shATGL BAs. Basal
gene expression of LCAD, MCAD, Cycs, COXII and COXIV were lower in shATGL cells.
Stimulation with the cAMP analogue 8-Br-cAMP for 24 h induced the expression LCAD, MCAD,
Cycs, COXII and COXIV in shCON BAs (Figure 21B). In contrast, the ability of 8-Br-cAMP to
upregulate the expression of genes involved in lipid oxidation and oxidative phosphorylation
was compromised in shATGL BAs (Figure 21B). Collectively, these results demonstrate that the
defect in the ability of shATGL to upregulate the expression of genes involved in fat oxidation
and mitochondrial function is at the level of ligand production.
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Figure 21. ATGL is required to maximally increase mitochondrial gene expression in
response to cAMP stimulation in brown adipocytes. A, brown adipocytes expressing a
control (shCON) or ATGL (shATGL) shRNA were treated with agonists against PPARα
(GW7647; 1 µM) and δ (L165; 5 µM) for 24 h. mRNA levels were measured by QPCR,
normalized to %PPIA and expressed as a fold of shCON. Measurements are from an average
of three independent experiments performed in duplicate. The effect of GW7647 or L165 in
comparison to Ctl is shown (***P < 0.001; **P < 0.01). The effect of ATGL knockdown is
shown (&&&P < 0.001; &P < 0.05). B, Indicated cells were treated with H2O (Ctl) or 8-Br-cAMP
for 24 h and mRNA levels were quantified by QPCR, normalized to %PPIA and expressed as a
percent of shCON 8-Br-cAMP. Measurements are from an average of four independent
experiments performed in triplicate. The effect of ATGL knockdown is shown (shATGL) (***P
< 0.001; **P < 0.01). Statistical analysis was performed by two-way ANOVA.

68
Finally, the effect of ATGL knockdown on mitochondrial biogenesis and mitochondrial
activity was examined. There was no difference in mitochondrial DNA content between shCON
and shATGL BAs (Figure 22A).

Treatment of BAs with 8-Br-cAMP for 48h increased

mitochondrial DNA content in shCON BAs and this effect was reduced in BAs with ATGL
knockdown (Figure 22A). Next, we measured mitochondrial activity in permeabilized BAs in
response to the addition of either a glycolytic (pyruvate) or FA substrate (palymitoyl-carnitine).
8-Br-cAMP increased coupled (ADP), and fully uncoupled (FCCP) respiration equally in shCON,
and shATGL cells when pyruvate was used as the substrate for oxidation (Figure 22B). 8-BrcAMP also increased oxidation of the FA substrate palmitoyl-carnitine (Pm-Carnitine) in shCON
cells. However, in contrast to pyruvate, oxidation of Pm-Carnitine was reduced in cells with
knockdown of ATGL. This difference between shCON and shATGL was more apparent when
mitochondria were fully uncoupled (FCCP), and electrons were allowed to fully pass through the
electron transport system without restriction (Figure 22B). These results indicate that FA
oxidation is limiting for mitochondrial electron transport in the shATGL BAs.
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Figure 22. ATGL is required to maximally increase fatty acid oxidation in response to cAMP
stimulation in brown adipocytes. A, mitochondrial DNA content (mtDNA) normalized to
nuclear DNA (nDNA) in shCON and shATGL brown adipocytes in control state (Ctl) or treated
with 8-Br-cAMP for 48 h. B, relative mitochondrial oxygen consumption rate (ROCR) in
permeabilized shCON and shATGL brown adipocytes using pyruvate or palmitoyl-carnitine
(Pm-Carnitine) as substrate. ADP driven (Pyruvate; Pm-Carnitine) and fully stimulated
(Pyruvate + FCCP; Pm-Carnitine + FCCP) respiration is shown. Measurements are from an
average of three independent experiments performed in duplicate. Statistical analysis was
performed by two-way ANOVA to determine the effect of ATGL knockdown (shATGL) (***P <
0.001; *P < 0.05; ns, non-significant).

70
5.6

Chapter 5 Discussion
Activation of the β3-AR promotes thermogenesis in WAT by mobilizing FAs that both

activate UCP1 and provide fuel for thermogenesis. β3-AR also increased the transcription of
thermogenic genes that expand the capacity for oxidative metabolism. The pathways of
lipolysis and gene transcription in BAT have previously thought to be independent events. This
chapter explored the interactions between these pathways and demonstrates that FFAs
potentiate PKA-dependent gene transcription in BAs.
We found that in BAs the optimal induction of PGC1α, PPARα, PDK4, and UCP1 mRNA by
PKA activation requires lipolysis. That HSL inhibition had an additive effect in ATGL knockdown
cells on the induction of thermogenic genes, indicating that lipolysis is a major pathway by
which β -ARs regulate thermogenic gene expression BAT. Importantly, the lipolysis-dependent
regulation of gene transcription was independent of the lipase, suggesting that both ATGL and
HSL produce similar ligands for PPARs. The promoter elements of PGC1α (Barberá et al. 2001),
PDK4 (Degenhardt et al. 2007), and UCP1 (Kozak et al. 1994) contain PPAR response elements
(PPREs), which likely define the means by which lipolysis regulates their expression. We note
that other pathways downstream of cAMP/PKA, like CREB (Karamitri et al. 2009), are important
in synergizing with PPARs for maximal gene expression in BAT (Kozak 2011).
Of debate is the nature and source of endogenous ligands for PPARs. Our current
results demonstrate PPARα and δ ligands are detected at the lipid droplet surface within
minutes of PKA activation and can transcriptionally activate PPARα and δ over hours.

The

generation of ligands for PPARα/δ was rapid, profoundly suppressed by HSL inhibition and
mimicked by exogenous OA. This indicates that mobilized FAs are likely endogenous ligands.
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The identity of the ligand produced during lipolysis is likely a long chain non-esterified fatty
acid, since increasing endogenous fatty acid levels by inhibition of ACSLs and CPT1 was
sufficient to elevate gene expression. It is likely that multiple endogenous PPAR α and δ ligands
exist, which vary by tissue, enzyme and metabolic status (Chakravarthy et al. 2009, Duncan et
al. 2010, Ravnskjaer et al. 2010, Ruby et al. 2010, Sanderson et al. 2009, Sapiro et al. 2009).
Knockdown of ATGL significantly reduced induction of the rate limiting enzymes for
mitochondrial fatty acid oxidation and impaired oxidation of fatty acids. Cells lacking ATGL
were fully responsive to exogenous PPARα and δ ligands suggesting that there is no defect at
the level of PPARs. Rather, ATGL is required for the full response to 8-Br-cAMP, indicating that
the defect in gene regulation is due to the lack of ATGL-dependent PPAR ligands. The
relationship between lipases and enzymes for β-oxidation suggests a feedback loop which
permits FA oxidation to be closely matched to mobilization. Thus, lipolytic products activate
PPARα and δ to enhance the oxidative phenotype of BAs (Figure 23).

Figure 23. Lipolytic products activate PPARα and δ to promote lipid oxidation in BAT. β3AR activation stimulates AC and PKA and subsequently ATGL and HSL to mobilize free fatty
acids (FFA) Lipolytic products are detected by PPARα and δ to match lipid oxidation with
the supply of FFAs. Other transcription factors (TF) such are CREB, likely function with PPARs
for optimal PKA-mediated gene transcription.
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Chapter 6. General Discussion
In the current study we have investigated the role of FA fate in promoting inflammation
and oxidation in white and brown adipose tissue, which at first glance seem to be of opposing
function. FAs have multiple fates (Figure 1), and an integrative understanding of how FAs signal
within AT is lacking. Intracellular FAs produce inflammation and limit oxidative gene expression
in WAT (Chapter 3 and 4). In contrast, lipolytic products in BAT activate PPARα and δ to
promote an oxidative phenotype (Chapter 5). Excess FFAs can be toxic, and the mechanisms by
which WAT and BAT deal with FA flux differ; however the outcome of limiting their detrimental
effects is similar. The work presented in chapter 3 and 4 suggests that FFAs are toxic when
their production exceeds efflux in WAT, which leads to the accumulation of intracellular FFA
(Figure 24).

Figure 24. Lipolytic products in white fat balance production with efflux. FFA fate in WAT
limits efflux by feedback inhibition on AC and by producing an inflammatory response. As a
consequence, PKA-mediated gene expression is reduced.
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In WAT, activation of lipolysis mobilizes energy for peripheral tissues. However, the
excessive mobilization of FAs is toxic when production exceeds FA handling and/or oxidation.
FA toxicity induced by β3-AR activation is initially limited by feedback inhibition on AC, which
effectively diminishes lipolysis.

Thus, feedback inhibition balances FA production with

subsequent metabolism (Chapter 4). We found that FFAs limit cAMP production and reduce
the expression of PKA-targeted genes by β3-AR activation. In this regard, treatments that limit
intracellular FAs by increasing FA handling or oxidation (Seufert et al. 2004) would be expected
to improve coupling of the β3-AR with PKA-targeted gene expression. Additionally, limiting
intracellular FFAs in WAT would have additional anti-inflammatory and possibly anti-diabetic
effects (Bensinger and Tontonoz 2008).
Activation of the β3-AR produces inflammation in WAT, a process marked by the
expression of inflammatory cytokines, and subsequent recruitment of myeloid cells that
surround fat cells (Granneman et al. 2005). The inflammation mounted by β3-AR activation is
likely another means of limiting FAs, and is reminiscent of the inflammatory state associated
with obesity. In obesity, activated macrophages surround necrotic adipocytes in order to
offload lipid (Cinti et al. 2005, Murano et al. 2008). The inflammation induced by β3-AR
activation can be considered a homeostatic response to lipid overload, and immune cells that
are recruited to AT likely function to scavenge lipid and impart anti-lipolytic effects that further
shut down lipolysis (Kosteli et al. 2010). However, β3-AR stimulation over days remodels WAT
in a reparative process whereby dysfunctional fat cells are replaced by new cells derived from a
population of PDGFRα+ progenitor cells (Lee et al. 2012). Under conditions of chronic β3-AR
agonism these PDGFRα+ progenitor cells differentiate into BAs (inducible BA; iBA), whereby
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EWAT takes on oxidative phenotype that diverts lipid towards β-oxidation. Interestingly, β3-AR
activation does not produce inflammation in BAT, in which FFAs are coupled to oxidation (see
below).
Although FA mobilization would be expected to initially have anti-diabetic properties,
chronic β3-AR activation improves insulin sensitivity.

At first, activation of the β3-AR

suppresses insulin action in white adipocytes (Jost et al. 2005), as it elevates FFA metabolites. It
may be that the acute availability of lipid as source of energy would initially diminish glucose
utilization, a hypothesis first suggested by Randle and colleagues in the 60’s (Randle et al.
1963). The improvement in insulin sensitivity seen with β3-AR agonists occur prior to changes
in body weight (Cawthorne et al. 1992), and are associated with elevated FA oxidation in WAT,
and a reduction in plasma FFAs (de Souza, Hirshman, and Horton 1997). Enhancement of FA
oxidation in WAT requires PPARα, which also promotes resolution of inflammation mounted by
β3-AR activation (Li et al. 2005). Interestingly, PPARα is highly expressed in BAT (Ahmadian et
al. 2011), where lipolytic products are ligands for PPARs (see below).
In BAT, activation of β3-AR does not produce inflammation; rather mobilized FAs
activate UCP1 to stimulate high rates of oxidation. We found that lipolytic products activate
PPARα and δ to promote the expression of thermogenic genes. Lipase action was required to
maintain FA oxidation in BAs.

Thus, activation of PPARα and δ by ATGL and HSL is a

homeostatic response to FFA mobilization that matches FA supply more closely with lipid
oxidation (Figure 25).
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Figure 25. Lipolytic products in BAT match supply with oxidation. FFAs in BAT activate
UCP1 and drives fatty acid oxidation. Lipolytic products in BAT are sensed by PPARα/δ to
further upregulate lipid oxidation.

We observed contrasting effects with HSL inhibition in WAT vs. BAT with respect to the
induction of oxidative genes. Furthermore, increasing intracellular FFAs in BAs enhanced the
expression of oxidative genes, while in white adipocytes it reduced their induction. Intracellular
FAs in WAT limit cAMP production, but whether similar mechanism exist in BAT seems unlikely
as the induction of NOR-1, a known PKA-target, was not potentiated in BAT, or in cultured BAs.
It is currently not known how FFAs might limit cAMP production in WAT, but not BAT. AC
isoforms are differentially affected by nucleoside inhibitors and forskolin (Hurley 1999), which
raises the possibility of differences in the sensitivity to FA antagonism.

Interestingly, AC3 is

highly expressed in BAT and is increased in response to neural and adrenergic stimulation, and
corresponds with enhanced AC activity (Chaudhry et al. 1996, Granneman 1995). It may be that
the differential expression pattern of AC isoforms between WAT and BAT accounts for the
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differences in FFAs limiting oxidative gene expression. Furthermore, the contrasting effects of
FFAs on gene expression in WAT and BAT could also be explained by the high levels of PPARα in
BAT (Ahmadian et al. 2011).
We found that lipid droplets are a source of PPARα and δ ligands in BAs. However, FA
spillover from adipose tissue leads to the accumulation of ectopic lipid in non-adipose tissues
that reduces insulin sensitivity. The formation of lipid mediators such as DAGs and ceramides
are critical in producing insulin resistance in skeletal muscle, liver and pancreatic beta cells
(Glass and Olefsky 2012). It seems likely that the cellular source of FAs (i.e. lipid droplet vs.
circulation) has an important role in determining their subsequent fate.

For example,

incomplete FA oxidation in muscle is thought to produce lipid mediators that cause insulin
resistance (Koves et al. 2008). Furthermore, in the heart, the formation of endogenous PPARα
ligands is thought to require hydrolysis from lipid droplets, as lipids from fatty acid uptake or
lipoprotein lipase are not sufficient to serve as active signaling molecules (Haemmerle et al.
2011). How FAs traffic to the nucleus and activate PPARs is currently not known, but might
involve FA binding proteins (Furuhashi and Hotamisligil 2008), or the recent identification of
nuclear lipid droplets (Layerenza et al. 2013). Thus, an important area of future work would be
to further understand cellular trafficking of FAs and the role that various organelles (i.e.
mitochondrial, endoplasmic reticulum) play in their signaling.
Our data from brown fat suggests that stimulating lipolysis would be beneficial in
activating BAT and likely enhancing its function. This finding has important clinical implications
considering the identification of functional BAT in humans (Ravussin and Kozak 2009).
Activation of lipolysis is of benefit in rodents, as overexpression of ATGL promotes an oxidative
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phenotype in WAT (Ahmadian et al. 2009), and mice with genetic alterations that increase
lipolysis have greater energy expenditure and are lean (Martinez-Botas et al. 2000, Nishino et
al. 2008, Tansey et al. 2001). However, whether stimulation of lipolysis would have similar
benefit in human is not known. Alternatively, human BAT could be activated with a dual
PPARα/δ agonist. That ATGL and HSL are known PPAR targets (Rakhshandehroo et al. 2007)
suggests that PPARα/δ agonism would create a feed forward loop between PPARs and lipases
to further enhance BAT function. Direct agonist treatment would not require lipase activity as
PPARα ligands rescue mice with ATGL deficiency in the heart from impaired cardiac function,
and premature death (Haemmerle et al. 2011).
In summary, data generated here demonstrate the controlling FA fate could be a means
of modulating AT function. Limiting the formation of intracellular FAs and ceramides and/or
sphingolipids would be of benefit. Activation of PPARα and δ could promote lipid oxidation in
BAT and likely other tissues, and limit lipotoxicity. Finally, the experiments proposed below
should further expand the role of lipases and lipids in controlling inflammation and cellular
metabolism.
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Chapter 7. Future Directions
7.1

To further determine the signals which promote inflammation in WAT during β3-AR

activation
Our early work indicated that the immune cells that are initially recruited to adipose
tissue with β3-AR activation are likely neutrophils (Mottillo, Shen, and Granneman 2010).
Further phenotyping of these cells by FACS will aid in understanding the interaction between
immunity and metabolism in WAT. Previous work and that presented here, demonstrate that
the expression of inflammatory cytokines and recruitment of immune cells is regulated by HSL
(Mottillo, Shen, and Granneman 2007). Understanding whether lipid mediators generated by
lipolysis (Finley et al. 2013, Spite et al. 2011), or the production of cytokines (Weisberg et al.
2006), are involved in immune cell recruitment of will be one area of focus. In addition, our
data indicate that ceramides/sphingolipids are involved in the production of cytokines,
therefore further interrogating ceramide and sphingolipid signalling in fat cells would be of
interest (Hla and Dannenberg 2012).

7.2

To further determine the trafficking of fatty acids with in cells
Understanding the cellular trafficking of FFAs will be critical in determining whether

other organelles can give rise to PPAR ligands. In addition, by expanding the use of the
fluorescent PPAR sensors to other organelles this will provide a spatial and temporal
understanding of how FAs traffic in cells. This will be part of larger goal to determine if specific
pool FFAs give rise to PPAR ligands, or otherwise lead to the formation of bioactive lipids such
as DAGs and ceramides.
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7.3

To determine whether direct activation of lipolysis is of benefit in rodents
A larger goal of the laboratory is to identify small molecules that stimulate lipolysis at

the level of lipases. Various genetic models indicate that enhancing lipolysis improves whole
body metabolism (Ahmadian et al. 2009, Martinez-Botas et al. 2000, Nishino et al. 2008, Tansey
et al. 2001). Future work will be focussed on determining if such small molecule activators of
lipolysis promote fat loss and improve insulin sensitivity in mice. Moreover, determining the
target tissues that are required to mediate the effects of such small molecules will be of
interest.

7.4

To determine whether ATGL is required for the browning of white fat
Previous studies have demonstrated that deletion of ATGL converts BAT to a WAT-like

tissue (Ahmadian et al. 2011). However, whether ATGL is required for the browning of WAT is
not known. The appearance of BA in EWAT and inguinal WAT (IWAT) by β3-AR activation
involve different mechanisms. BAs in IWAT appear from the direct conversion of pre-existing
adipocytes (Barbatelli et al. 2010). In contrast, the appearances of BAs with chronic β3-AR
agonism derive from a population of PDGFRα+ progenitors (Lee et al. 2012). By deleting ATGL
specifically in AT in an inducible manner (via CreERT2 technology), we will be able to test
whether adipocyte ATGL is required for the appearance of BA in WAT of mice. These studies
could have important implication in understanding how BAs in adult humans are formed.
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Adipose tissue (AT) is a critical regulator of energy balance through its ability to store or
oxidize free fatty acids (FFAs). White adipose tissue (WAT) functions as an anabolic organ to
sequester and release FAs, in contrast brown adipose tissue (BAT) is a catabolic organ that
oxidizes FAs. However, a comprehensive understanding of the role that FFAs play in the
function of WAT and BAT is needed. Here we demonstrate that intracellular FAs enhance the
expression of inflammatory cytokines by β3-AR activation in adipocytes, in which the
expression of PAI-1 is partly mediated by the de novo synthesis of ceramides/sphingolipids. We
also explored the relationship between lipolysis and oxidative gene expression in AT. β3-AR
stimulation increased the expression of oxidative genes (PCG1α, UCP1 and NOR-1) in WAT of
mice, which was greatly potentiated by inhibition of hormone sensitive lipase (HSL). In 3T3-L1
adipocytes, limiting lipolysis potentiated the induction of oxidative genes; while in contrast,
promoting the accumulation of intracellular FAs suppressed their induction by β-AR stimulation.
Interrogation of the β-adrenergic signalling pathway indicates that intracellular FAs inhibit
adenylyl cyclase activity and thereby reduce PKA-mediated transcriptional activity. Partially
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limiting lipolysis enhanced the induction of brown fat markers and mitochondrial electron
transport chain activity in WAT, and facilitated fat loss in mice treated with a β3-AR agonist for
five days. In contrast to the results observed in WAT, HSL activity was required for the
induction of PGC1α, PPARα, PDK4 and UCP1 by β3-AR activation in BAT of mice. Similarly,
lipolysis was required for the maximal induction of oxidative genes in cultured brown
adipocytes (BAs), while increasing endogenous FAs elevated their expression. Pharmacological
antagonism and siRNA knockdown indicate that PPARα and δ mediate the induction of
oxidative genes by β-AR agonism. Dynamic imaging studies demonstrate that lipids droplets
are a source of ligands that transcriptionally activate PPARα and δ. Finally, lipolysis was
required to maintain the expression of mitochondrial genes, and FA oxidation in BA. Overall,
results indicate that in WAT excess FFAs are toxic, and function to balance production with
efflux, while in BAT FFAs promote oxidation, and match FA oxidation with supply. These finding
suggest that limiting intracellular FAs is WAT, and activation of PPARα/δ would be of benefit in
preventing the toxic effects of FAs, which could have implications for treating excess adiposity
and diabetes.
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